Common Gene Variants in Schizophrenia Susceptibility with Focus on Neurodevelopment by Kähler, Anna K.
  
 
 
 
Common Gene Variants in 
Schizophrenia Susceptibility  
with Focus on Neurodevelopment 
 
Anna K. Kähler 
 
 
Faculty of Medicine 
University of Oslo 
2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Anna K. Kähler, 2009 
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 860 
 
ISBN 978-82-8072-355-0 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AiT e-dit AS, Oslo, 2009.   
 
Produced in co-operation with Unipub AS.  
The thesis is produced by Unipub AS merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 
Unipub AS is owned by  
The University Foundation for Student Life (SiO) 
3 
 
 
4 
 
Table of Contents 
 
1. ACKNOWLEDGEMENTS ....................................................................................................... 6 
2. LIST OF PAPERS .................................................................................................................... 8 
3. ABSTRACT ............................................................................................................................... 9 
4. ABBREVIATIONS .................................................................................................................. 10 
5. INTRODUCTION ..................................................................................................................... 12 
5.1 SCHIZOPHRENIA: PHENOTYPE, EPIDEMIOLOGY, TREATMENT .............................................. 12 
5.2 SCHIZOPHRENIA ETIOLOGY: MAIN HYPOTHESES .................................................................. 13 
5.2.1 The dopamine hypothesis ................................................................................... 13 
5.2.2 The glutamate hypothesis ................................................................................... 14 
5.2.3 The neurodevelopmental hypothesis............................................................... 15 
5.3 THE MAIN DOMAINS OF NEURODEVELOPMENT AND PLASTICITY IN THIS THESIS .................. 18 
5.3.1 Neuronal migration ............................................................................................... 18 
5.3.2 Perineuronal networks and the HNK-1 pathway ........................................... 19 
5.4 HUMAN GENETICS AND DISEASE MAPPING ........................................................................... 20 
5.4.1 The human genome and genetic variation ..................................................... 20 
5.4.2 Linkage disequilibrium ........................................................................................ 21 
5.4.3 The international HapMap project and tag SNPs .......................................... 22 
5.5 ASSOCIATION STUDY DESIGN ............................................................................................... 23 
5.5.1 Candidate genes or the whole genome? ......................................................... 24 
5.6 GENETICS AND SCHIZOPHRENIA .......................................................................................... 25 
5.6.1 A complex disorder with high heritability ....................................................... 25 
5.6.2 Linkage studies, positional candidates, chromosomal abnormalities .... 26 
5.6.3 Candidate based association studies .............................................................. 27 
5.6.4 Genome wide association studies (GWAS) .................................................... 27 
5.6.5 Studies of copy number variations (CNVs) .................................................... 28 
5.6.6 Genetic studies using endophenotypes and clinical features .................. 29 
5.7 GENETIC OVERLAP OF BIPOLAR DISORDER AND SCHIZOPHRENIA ....................................... 30 
5.8 AIMS OF THE STUDY ............................................................................................................. 32 
6. MATERIALS AND METHODS ............................................................................................. 33 
6.1 STUDY SAMPLES ................................................................................................................... 33 
6.1.1 SCOPE schizophrenia sample description ..................................................... 33 
6.1.2 SCOPE bipolar disorder sample description ................................................. 35 
6.1.3 SGENE-plus sample description ....................................................................... 36 
6.1.4 Clinical features and endophenotypes in the TOP study ........................... 36 
6.1.5 Genetic features of the TOP sample................................................................. 37 
6.2 THE CANDIDATE GENES STUDIED ......................................................................................... 39 
6.3 GENOTYPING TECHNOLOGIES .............................................................................................. 40 
6.4 STATISTICS ........................................................................................................................... 42 
6.4.1 Statistical tests and methods ............................................................................. 42 
6.4.2 The statistical softwares ..................................................................................... 45 
7. SUMMARY OF RESULTS .................................................................................................... 48 
8. DISCUSSION .......................................................................................................................... 53 
8.1 FINDINGS AND INTERPRETATIONS ........................................................................................ 53 
8.1.1 Major risk alleles in B3GAT2 and GRIK3 ......................................................... 53 
8.1.2 Schizophrenia and neuronal migration ........................................................... 56 
5 
 
 
 
 
8.1.3 Common genetics for schizophrenia and bipolar disorder ........................ 57 
8.1.4 Gender-specific associations of PDE4B tagSNPs with schizophrenia ... 58 
8.1.5 Associated genes and regional schizophrenia linkage............................... 59 
8.1.6 Genetic effects on symptoms, neurocognition, and age at onset ............ 60 
8.2 GENERAL METHODOLOGICAL ISSUES ................................................................................... 62 
8.2.1 The schizophrenia and bipolar disorder phenotype .................................... 62 
8.2.2 Strategies for picking tagSNPs .......................................................................... 63 
8.2.3 Power, control selection, and population stratification .............................. 64 
8.2.4 Correction for multiple testing ........................................................................... 67 
9. CONCLUDING REMARKS AND FUTURE STUDIES ...................................................... 69 
10. CONCLUSIONS ...................................................................................................................... 71 
11. ERRATA................................................................................................................................... 72 
12. REFERENCES ........................................................................................................................ 74 
 
 
 
6 
 
1. Acknowledgements 
The studies reported in this thesis were carried out during the years 2006-2009 at the 
Department of Psychiatry and Department of Medical Genetics, Oslo University Hospital – 
Ullevål, as well as at the Institute of Psychiatry, University of Oslo. The study was part of the 
Thematically Organized Psychosis Research (TOP) Study. I am grateful for the support from 
the Research Council of Norway, Eastern and Western Norway Health Authority, Oslo 
University Hospital-Ullevål and the University of Oslo to support the TOP Study group, as 
well as the the Sigurd K. Thoresens legat. 
 
During my years as a PhD student I have received support and encouragement from many 
people and I would like to express my sincere gratitude to all of you; my supervisors, co-
authors, collaborators, colleagues, family and friends. In particular I would like to thank: 
 
Professor Ole A. Andreassen, my main supervisor, and Principal Investigator of the TOP 
Study, for giving me the opportunity and aims to perform this thesis work, for your constant 
enthusiasm, your research ideas, and for being available, almost literally whenever I have 
needed feedback or help. Dr. Srdjan Djurovic, my co-supervisor and head of the TOP 
Molecular Genetics group, for your research input and our discussions over the years, and 
also for being a good friend. Thank you for your hospitality and efforts in trying to make me 
work a little less and get my priorities right during stressful times. Professor Vidar M. Steen, 
my co-supervisor at the University of Bergen, for great scientific discussions, and thorough 
and very useful input on my projects and in the writing process.   
 
The SCOPE collaborators and co-authors in Denmark, Sweden, and Trondheim: Thomas 
Werge, Thomas Hansen, Klaus D. Jakobsen, Erik Jönsson, Ingrid Agartz, Håkan Hall, Ole 
Mors, Erling Mellerup, Pernille Koefoed, Gunnar Morken. A special thank to Thomas and 
Thomas for a lot of fun on conferences and meetings, and great scientific discussions, and 
thank you Thomas H for our nice Skype chats; and to Ingrid, also head of the TOP sMRI 
group, for introducing me to the TOP study. The collaborators of the SGENE-plus study, for 
providing replication data, and a special thank to Stacy Steinberg and Omar Gustafsson for 
coordination. 
 
My colleagues and co-authors of the TOP study: Ingrid Melle, Mona Otnæss, Stein 
Opjordsmoen, Katrine Wirgenes, and Bettina Kulle, for good collaboration and interesting 
talks. Russell T. Matthews, for a great collaboration, and Stephanie Hellard, for interesting 
research discussions and advice. 
 
Everyone at the Department of Medical Genetics, Ullevål, for nice times in the lab, fun 
conferences and parties. A special thank to Dag Undlien, head of the research section, for 
letting me be a part of your research environment; Hanne Akselsen for lab-related help and a 
lot of fun; and to Kristin Brandal, for being both invaluable in the lab as a tutor and pipetting 
robot expert, and also a great friend. Thank you for our cozy Mucho Mas-dinners and for the 
nice conference & vacation in Barcelona. 
 
The lab technicians of the TOP Molecular Genetics group, Elin Inderhaug, Knut-Erik Gylder,  
7 
 
 
 
 
 
Trude Lien, and Marie Skogstad, for your skilful assistance in the lab, for nice chats, fun 
parties, and for creating such an enjoyable work environment.   
 
All other colleagues of the TOP study group, especially those at the Ullevål department for 
creating such a fantastic work environment, for nice lunches, chats in the kitchen, and 
research discussions. A special thank to Ingrid Melle, co-leader of the TOP-study; Thomas D. 
Bjella, Ragnhild Bettina Storli, and Eivind Bakken for administrative and database assistance; 
my office room-mate Lavinia, and Lars Morten, for fun talks about science and life; Beathe 
(my favorite Norwegian girl), for being a close friend,  for a lot of laughter, and invaluable 
talks. 
 
Morten Mattingsdal for being such a nice office room-mate during my first months in Oslo, 
and for providing help with figures and bioinformatics. Trygve Bakken, for figure 2 of this 
thesis. Øivind Skare, for skilful help on R matters. 
 
My new friends who have made my time in Oslo so much more fun, especially: Beathe, 
Kathrine, Karine, Ingrid, Britt-Helen, Anne-Marta, Johnny, and Morten. A huge thank to 
Beathe & Johnny, and Kathrine & Morten, for opening your homes to me. Thank you 
Kathrine, for being so kind, open, and easy going, and for my first meat tacos in 12 years.   
 
Irene, for our friendship, and also good collaboration on our schizophrenia – toxoplasma 
project, that we ought to finish soon. Lina, for being a very appreciated friend, and former 
colleague, and for our nice trip to Cambridge. 
 
My two best friends: Karin for a lot of laughter and telephone talks over the last 20 years, and 
for putting up with me, despite my time optimism and work focus during the last years (and 
thank you to boyfriend Mats for a lot of fun); Hellis, for being the perfect friend almost since 
the day we first met, always being there for me, and making me laugh, for fun party nights 
and all events you’ve arranged or invited me to, for your thoughtfulness and constant support.  
 
Berit and Øystein, Christoffer and Sara, for really making me feel welcome and part of the 
family. Jonas, for the too short but exciting time I got to spend with you, for great stories, 
discussions, and a fantastic trip to Thailand.  
 
My fantastic family: Mum and dad, for your continuous love and support, for always helping 
me out when I have needed it, with everything from late night advice to carrying moving 
boxes. Magnus, for a lot of laughter, support and good talks, for being the best brother! Min 
kära mormor, för alla härliga skogspromenader och samtal, du är min idol! Gunilla, Bengt-
Göran, David and Ida, for all nice and fun times we have had together over the years.    
 
Magnus, for your love, encouragement, thoughtfulness, patience with my working hours and 
genetics talk, for spoiling me with your fantastic food creations and funny thoughts, for all 
our lovely late dinners and amusing discussions, and for critically reading my thesis. You’re 
the best accompanying person ever. I love you! 
8 
 
2. List of Papers 
This thesis is based on the following publications, which will be referred to by their 
roman numerals: 
Paper I. 
Kähler AK, Djurovic S, Kulle B, Jonsson EG, Agartz I, Hall H, Opjordsmoen S, Jakobsen 
KD, Hansen T, Melle I, Werge T, Steen VM, Andreassen OA (2008).                                        
Association analysis of schizophrenia on 18 genes involved in neuronal migration: MDGA1 as 
a new susceptibility gene.                                                                                                                              
American Journal of Medical Genetics: Part B Neuropsychiatric Genetics 147B:1089-100. 
Paper II. 
Kähler AK, Otnæss MK, Wirgenes KV, Hansen T, Jönsson EG, Agartz I, Hall H, Werge T, 
Morken G, Mors O, Mellerup E, Dam H, Koefod P, Melle I, Steen VM, Andreassen OA, 
Djurovic S (2009).                                                                                                        
Association study of PDE4B Gene Variants in Scandinavian Schizophrenia and Bipolar 
Disorder multicenter case-control samples.                                                                                                           
American Journal of Medical Genetics: Part B Neuropsychiatric Genetics [Epub ahead of 
print] 
 
Paper III. 
Kähler AK, Djurovic S, Agartz I, Wirgenes KV, Jönsson EG, Hansen T, Hall H, Giegling I, 
Muglia P, Cichon S, Rietschel M, Pietiläinen OPH, Peltonen L, Bramon E, Collier D, St Clair 
D, Sigurdsson E, Petursson H, Rujescu D, Gustafsson O, Melle I, Werge T, Steen VM, 
Matthews RT,  Andreassen OA.  
A Study of Ten Genes in the HNK-1 Pathway and Perineuronal Nets: B3GAT2 is associated 
with schizophrenia in two large European Multi-Center Case Control Samples  
submitted 
                                                                                                                        
Paper IV. 
Djurovic S, Kähler AK, Kulle B, Jönsson EG, Agartz I, Le Hellard S, Hall H, Jakobsen KD, 
Hansen T, Melle I, Werge T, Steen VM, Andreassen OA (2009). 
A possible association between schizophrenia and GRIK3 polymorphisms in a 
multicenter sample of Scandinavian origin (SCOPE). 
Schizophrenia Research 107:242-248. 
 
9 
 
3. Abstract 
Schizophrenia is a severe multifactorial mental disorder with an important and complex 
genetic component, and the understanding of the underlying biological mechanisms is limited. 
Several lines of evidence support that abnormal neurodevelopment is involved, such as 
cognitive deficits in children who later develop schizophrenia, abnormalities in brain structure 
in the early phase of disease, and aberrant neuronal distributions. Also, glutamatergic 
dysfunctions are suggested in the schizophrenia etiology, and glutamate signalling is 
important during neurodevelopment. Perineuronal nets are extracellular matrix structures 
involved in brain maturation, which includes the characteristic neural epitope Human Natural 
Killer-1 (HNK-1).  
To investigate if common gene variants important for neurodevelopment are involved 
in schizophrenia etiology, we used candidate gene-based association studies of tagSNPs 
spanning thirty genes, genotyped in a large Scandinavian case-control sample (SCOPE).  
Nineteen, out of the 289 tagSNPs in 18 neuronal migration genes, were nominally 
significant, and the strongest finding was a tagSNP located in MAM domain containing 
glycosylphosphatidylinositol anchor 1 (MDGA1), but no findings were significant after 
correction.  
Phosphodiesterase 4B (PDE4B) is a Disrupted-in-Schizophrenia-1 (DISC1) interactor, 
with previously reported genetic associations only in women. Six and 16, out of 40 and 72 
PDE4B tagSNPs, were nominally associated with schizophrenia and bipolar disorder, 
respectively, in the combined samples or in gender-specific subgroups. No findings were 
significant after correction. However, two of the tagSNPs nominally associated in 
schizophrenia females had proxies which were nominally associated in the total bipolar 
disorder sample, and the four SNPs were located in the same block, surrounding the splice 
site for the PDE4B3 isoform.  
Five out of 104 tagSNPs in ten genes involved in perineuronal net formation and 
HNK-1 biosynthesis, located in beta-1,3-glucuronyltransferase 2 (B3GAT2), were nominally 
associated with schizophrenia. The association signal for tagSNPs in one of the LD blocks 
was replicated by proxy SNPs in a much larger European sample (SGENE-plus).  
Six out of 30 tagSNPs in glutamate receptor ionotrophic kainate 3 (GRIK3) were 
nominally associated, and the best tagSNP were significant after correction, with increased 
significance in the Swedish subsample, as well as when the risk allele was combined with 
another tagSNP risk allele.  
When investigating clinical characteristics, including positive and negative symptom 
scores, age at onset, and cognitive measures of learning, memory and IQ, for association with 
a subset of the tagSNPs and genes included in the thesis studies, there were no significant 
associations after correction.  
The current results indicate that gene variants involved in neurodevelopment are 
associated with schizophrenia, which further supports the neurodevelopmental hypothesis.  
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5. Introduction 
5.1 Schizophrenia: phenotype, epidemiology, treatment  
Schizophrenia is a severe mental disorder affecting approximately 1% of the general 
population, with onset in late adolescence or early adulthood. It is one of the major 
causes of disability worldwide, ranked as one of the most costly disorders to afflict 
humans [Murray, 1996]. The schizophrenia phenotype is characterized by the presence 
of positive symptoms (delusions, hallucinations and other distortions of reality), 
negative symptoms (loss of motivation, inability to experience pleasure, poverty of 
speech, lack of initiative, apathy, and reduced social drive), cognitive impairment, and 
mood symptoms [Tandon et al., 2008; Tandon et al., 2009]. The negative symptoms 
could be primary or secondary, the first if being fundamental to schizophrenia, and the 
latter when being caused by for example antipsychotic drug treatment or depression. 
The cognitive deficits is a core feature in schizophrenia, and domains affected are e.g. 
speed of processing, attention, working memory, verbal learning and memory, visual 
learning and memory, reasoning and problem solving, verbal comprehension, and 
social cognition [Nuechterlein et al., 2004]. Abnormal brain activation, as measured by 
functional brain imaging, have been associated with cognitive deficits [Greene et al., 
2008]. The schizophrenia phenotype is complex, and the diagnosis is solely based on 
the symptoms presented, implemented in the main diagnosis systems Diagnostic and 
Statistical manual of Mental disorders, 4th edition (DSM-IV) [American Psychiatric 
Association, 1994] and International Classification of Diseases, 10th revision (ICD-
10) [World Health Organization, 1992].  
 
There are indications of gender difference in schizophrenia, with  earlier age at onset, 
and a higher lifetime disease risk reported for males (male-female relative risk of 1.35) 
[Aleman et al., 2003]. Migrant status, urbanicity, prenatal starvation and infection, 
winter/spring birth, perinatal and obstetric complications (OCs), and older paternal 
age, are also associated with increased risk for schizophrenia [McGrath, 2007]. 
 
The antipsychotic medications used to treat schizophrenia are grouped into the so-
called typical or first generation (e.g. chlorpromazine, haloperidol), and the atypical or 
second generation (e.g. clozapine, olanzapine) antipsychotics. Both groups have strong 
affinity to the dopamine D2 receptor (see 5.2.1), which seems to be essential for the 
antipsychotic effect. The clinical effect is mainly similar, but the typical antipsychotics 
are known for extrapyramidal side effects, such as tardive dyskinesia, and elevated 
serum prolactin levels, while the atypicals have less motor side effects, but instead 
metabolic side effects such as weight gain. It has been shown that typical drugs bind to  
13 
 
 
the D2 receptors more tightly than the atypicals, and the latter also block 5-HT2A-
receptors [Seeman, 2002]. 
 
5.2 Schizophrenia etiology: main hypotheses 
5.2.1 The dopamine hypothesis 
Abnormal dopamine neurotransmission has long been implicated in schizophrenia 
etiology [Carlsson and Lindqvist, 1963; Carlsson et al., 1957], and the dopamine 
hypothesis was further based on data showing that the treatment outcome of 
antipsychotic drugs depended on their dopamine receptor affinity [Creese et al., 1976; 
Seeman and Lee, 1975], and the ability of the dopamine agonist amphetamine to 
induce psychosis. The main view was that a general increase in dopaminergic 
neurotransmission was involved in schizophrenia pathology. In a revised hypothesis,  a 
co-occurrence of both increased and decreased dopamine activity was suggested, 
namely prefrontal hypodopaminergia and subcortical hyperdopaminergia, causing 
negative and positive symptoms, respectively [Davis et al., 1991].                                                  
 
In a recent review, the main findings the last two decades in support of the dopamine 
hypothesis are discussed, and five main domains are highlighted, pointing towards a 
focus on presynaptic striatal hyperdopaminergia in schizophrenia pathology [Howes 
and Kapur, 2009]. Firstly, results from neurochemical imaging have revealed several 
abnormalities in schizophrenia patients, such as: increased striatal presynaptic 
dopamine synthesis, consistently reported in all studies investigating patients during 
acute psychosis; increased striatal dopamine release upon neuronal challenge, as well 
as dopamine baseline occupancy of D2 receptors; increased level of striatal D2/3 
receptor density, as well as an association between prefrontal cortical D1 receptor 
intensities with cognitive impairment and negative symptoms, independent of 
antipsychotic medication. Also, all licensed antipsychotic drugs are striatal D2 receptor 
blockers. Secondly, environmental factors, such as lack of close friends, urban 
upbringing, migration, complications during pregnancy and birth, as well as 
psychoactive substance abuse have been associated with increased risk of 
schizophrenia, and an overactivity of the dopamine system in response to the same 
factors or linked experiences has been reported in animal studies. Thirdly, increased 
risk of schizophrenia has been associated with interactions between gene variants 
involved in the dopamine system and environmental factors; the interaction between a 
variant of the cathechol-O-methyltransferase (COMT) gene, an enzyme involved in 
dopamine degradation, and cannabis use, was associated with increased risk for 
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psychosis. Fourthly, it has been reported that individuals at-risk for psychosis, such as 
those in the prodromal state or family members of patients with schizophrenia, show 
dopaminergic abnormalities and brain structural changes in areas linked to striatal 
dopaminergic function in animals. Finally, variants of genes involved in the dopamine 
system have been implicated in schizophrenia etiology [Glatt and Jonsson, 2006; 
Talkowski et al., 2008].       
 
5.2.2 The glutamate hypothesis 
The amino acid glutamate is the major excitatory neurotransmitter of the brain, and its 
receptor signaling is essential for excitatory neurotransmission, neuronal development 
and synaptic plasticity. The glutamate actions are mediated through three ionotropic 
receptor classes, N-methyl-D-aspartate (NMDA), α-amino-3-hydroxyl-5-methyl-4-
isoxazole-propionate (AMPA), and kainate (KA), and three groups (I, II, III) of 
metabotropic glutamate receptors [Kew and Kemp, 2005]. Glutamate can also exert 
receptor-mediated excitotoxicity leading to neuronal damage in the central nervous 
system [Greenamyre, 1986]. 
 
The hypothesis that hypofunction of the glutamate transmitter system is involved in 
the etiology of schizophrenia was first suggested almost three decades ago, when low 
levels of glutamate in cerebrospinal fluid (CSF) from patients with schizophrenia was 
reported [Kim et al., 1980]. Although later CSF findings have been inconsistent 
[McCullumsmith et al., 2004], other subsequent discoveries have provided strength to 
the glutamate hypothesis of schizophrenia [Coyle, 2006; Olney and Farber, 1995]. 
 
Specifically, hypofunction of the NMDA receptor has been suggested, which might be 
due to for example increased presence of endogenous NMDA antagonists or reduced 
release of glutamate. The exposure to NMDA antagonists, such as the dissociative 
anaesthetics phencyclidine (PCP) and ketamine, have been shown to trigger 
schizophrenia-like positive and negative symptoms in normal human subjects [Javitt 
and Zukin, 1991; Krystal et al., 1994; Luby et al., 1962], and increase psychotic 
symptoms in patients with schizophrenia [Lahti et al., 2001], which is not sufficiently 
explained by their dopamine dysregulation [Javitt and Zukin, 1991]. Also, NMDA 
antagonists cause permanent structural changes in several cerebrocortical and limbic 
regions in rats [Ellison, 1994; Olney et al., 1989], and the vulnerability to the 
neurotoxic effects is age-dependent, with susceptibility onset, or markedly increased 
susceptibility, in late adolescence of rats [Farber et al., 1995] and humans [Sussman, 
1974], respectively, similar to the age of schizophrenia onset in late adolescence and 
early adulthood. The endogenous NMDAR antagonist neuropeptide N-
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acetylaspartylglutamate (NAAG) was increased in the hippocampus of postmortem 
brains of schizophrenia patients, compared with both neuroleptic-treated, and non-
treated, controls [Tsai et al., 1995]. NAAG is catabolized into glutamate and NAA, 
and the activity of the responsible peptidase was reduced in the same study, both in 
schizophrenia hippocampus and prefrontal cortex, accompanied by reductions of 
glutamate in the same regions. These findings are in line with the NMDAR 
hypofunction hypothesis of schizophrenia.  
 
To move beyond the NMDA receptors, the above mentioned NAAG also selectively 
activates the metabotropic receptor mGluR3 [Wroblewska et al., 1997]. Another 
agonist for mGluR3/4 (the group II of metabotropic glutamate receptors) was shown to 
reverse the cognitive and behavioral abnormalities in the PCP-animal model of 
schizophrenia, without reducing dopamine release [Moghaddam and Adams, 1998]. 
More recent clinical evidence suggests that an mGluR3 agonist is an effective new 
approach in the treatment of schizophrenia [Patil et al., 2007]. The gene encoding 
mGluR3, GRM3 (alias MGLUR3), has been implicated in schizophrenia susceptibility 
and cognitive function [Egan et al., 2004; Harrison and Weinberger, 2005]. In 
addition, aberrant copy-number of three loci were found in two small samples of brain 
tissue from patients with schizophrenia and bipolar disorder, but not in controls 
[Wilson et al., 2006]. These loci included three genes involved in glutamate signaling, 
e.g. the KA receptor subunit gene glutamate receptor, ionotropic, kainate 3 (GRIK3) 
[Wilson et al., 2006]. Changed GRIK3 expression was shown in cortical and 
hippocampal regions of postmortem brains from schizophrenia patients compared with 
controls [Benes et al., 2001; Sokolov, 1998].  
 
5.2.3 The neurodevelopmental hypothesis 
The evidence for a neurodevelopmental etiology of schizophrenia is based on several 
domains, such as cognitive deficits in children who later develop the disease, and 
abnormalities in brain structure and neuronal distributions in schizophrenia patients 
compared with controls [Arnold et al., 2005; Harrison and Weinberger, 2005]. There is 
a lack of astrogliosis in post-mortem brain tissue [Falkai et al., 1999], which is present 
in neurodegenerative disorders [Rodriguez et al., 2009]. Background details for some 
of the main supportive areas are given below. 
 
Macroscopic neuropathology     
Already in the seventies, enlarged ventricles were shown to be associated with both 
schizophrenia and increased cognitive impairment among patients [Johnstone et al., 
1976]. A high number of brain imaging studies of schizophrenia patients have been 
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performed since then, and ventricle enlargement is among the most frequent structural 
findings [Vita et al., 1997; Vita et al., 2000]. In a review of 193 structural magnetic 
resonance imaging (sMRI) studies, several abnormalities of the brains of 
schizophrenia patients are reported, with the most robust findings being: lateral and 
third ventricular enlargement, medial temporal lobe reductions (including amygdala, 
hippocampus, and parahippocampal gyrus), superior temporal gyrus (STG) gray 
matter reductions, and enlarged cavum septi pelucidim, with all present in first-episode 
patients [Shenton et al., 2001]. Two recent meta-analyses reported reduced whole 
brain and hippocampus volumes, and increased ventricular volumes, in first-episode 
schizophrenia [Steen et al., 2006; Vita et al., 2006]. Another meta-analysis showed 
reduced hippocampal and total grey matter volumes, as well as enlarged third 
ventricular volume, in non-psychotic relatives of patients with schizophrenia [Boos et 
al., 2007]. The cortical structure has been investigated with sMRI for a subset of 
Swedish and Norwegian schizophrenia spectrum patients and controls included in the 
present thesis, and thinner prefrontal and temporal cortex was observed among patients 
compared with controls [Nesvag et al., 2008; Rimol et al., submitted], which was also 
shown in another study of patients who were off medication at least two weeks prior to 
the sMRI scan [Hazlett et al., 2000]. 
 
Important to note is that the brain structural abnormalities reported are subtle and not 
present in all patients with schizophrenia, rather are based on group means with 
substantial overlap between patients and controls [Shenton et al., 2001]. In addition, 
the potential confounding of antipsychotic medication, substance abuse, and chronic 
illness, on brain structural abnormalities, is a concern. However, the presence of 
structural abnormalities in first-episode schizophrenia patients [Steen et al., 2006; Vita 
et al., 2006], in relatives of patients with schizophrenia [Boos et al., 2007], and in anti-
psychotic-naïve patients [Szeszko et al., 2003], is in line with a potential genetically 
determined neurodevelopmental origin.  
 
Microscopic neuropathology                                                                                               
Abnormal cytoarchitecture of neurons in the entorhinal cortex, such as heterotopic 
displacements of cortical layer II neurons, is a histological finding reported in several 
studies of post-mortem brains from schizophrenia patients [Arnold et al., 1991; Arnold 
et al., 1997; Jakob and Beckmann, 1986; Kovalenko et al., 2003], but which was not 
found by others [Akil and Lewis, 1997; Bernstein et al., 1998]. Changed neuronal 
distribution in the prefrontal cortex was reported [Kalus et al., 1997]. In addition, 
subcortical interstitial neurons in prefrontal white matter were shown to have a 
changed distribution, with reduced densities in the superficial, but increased densities 
in the deeper white matter, in a subgroup of schizophrenia patients but in none of the 
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controls [Akbarian et al., 1993; Akbarian et al., 1996], which was not replicated in a 
subsequent study [Beasley et al., 2002]. Others found higher overall neuronal densities 
in prefrontal white matter tissue of schizophrenia individuals, which was most 
apparent in the more superficial parts [Anderson et al., 1996]. Taken together, results 
are conflicting and cannot yet be either confirmed or rejected. A limiting factor in 
these studies is the use of post-mortem tissue, where many factors not specific to 
disease development can influence the results. If the cytoarchitectural abnormalities 
are indeed causative, these imply an involvement of early neurodevelopment in 
schizophrenia etiology, affecting neuronal migration and brain connectivity. Interstitial 
neurons represent remaining early neurons of the subplate, which is important for the 
cortical development and connectivity [Kanold, 2004]. Other examples of 
cytoarchitectural aberrancies reported in post-mortem brain tissue of schizophrenia 
patients are smaller size of hippocampal neurons [Arnold et al., 1995; Benes et al., 
1991; Zaidel et al., 1997], and synaptic abnormalities in a number of hippocampal 
studies [Harrison and Eastwood, 2001]. These early brain abnormalities could be 
genetically determined, but also caused by other factors such as OCs and toxic agents.     
 
Premorbid cognitive and behaviour findings                                                                               
Cognitive deficits in childhood have consistently been associated with increased risk 
for schizophrenia [Maccabe, 2008]. Using large birth cohorts, childhood abnormalities 
in cognitive function, language and behaviour of both individuals who later develop 
schizophrenia and their unaffected siblings have been reported at higher rates, 
compared with non-psychiatric control subjects [Bearden et al., 2000; Cannon et al., 
2000; Jones et al., 1994; Niendam et al., 2003]. Overall cognitive functioning, as 
measured by full intelligence scales, was shown to be compromised both in future 
schizophrenia cases and their unaffected siblings, as early as at the age of 4 and 7 
years [Cannon et al., 2000]. The findings were not significantly associated with OCs or 
birth weight. Also, early childhood focal deviant behaviour (e.g. meaningless laughter, 
excessive crying, echolalia), and poor expressive language ability, predicted the 
outcome as schizophrenia patient and unaffected sibling, whereas social 
maladjustment was associated with schizophrenia outcome only [Bearden et al., 2000]. 
Moreover, delayed childhood motor development was associated with schizophrenia 
later in life, and with adult cognitive function [Murray et al., 2006]. Lower adolescent 
IQ has also been associated with higher risk for schizophrenia-spectrum disorders 
when investigating army conscripts [Reichenberg et al., 2006]. The findings that 
higher numbers of children who later develop schizophrenia, and their unaffected 
siblings, show developmental abnormalities early in life, suggest that these deficits are 
susceptibility phenotypes for schizophrenia. The fact that also unaffected siblings 
show similar patterns of impairment, also imply that these domains are heritable 
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phenotypes which are associated with an increased risk for schizophrenia but not 
causal themselves. That this instead should be the cause of shared environment is less 
likely, since several of the studies corrected for parental education and socioeconomic 
status [Bearden et al., 2000; Cannon et al., 2000; Niendam et al., 2003].  
 
Neurodevelopmental genes and susceptibility to schizophrenia 
Some of the genes which have emerged as strong schizophrenia susceptibility 
candidates, are involved in neurodevelopmental processes, and initially implicated in 
studies with no prior mechanistic hypotheses. In a study of a balanced translocation in 
a large Scottish family, segregating with severe mental illness such as schizophrenia, 
the gene Disrupted-in-Schizophrenia-1 (DISC1) was found to be disrupted [Millar et 
al., 2000]. Neuregulin 1 (NRG1) was originally implicated in schizophrenia after LD 
mapping across the linked region 6p24-22 [Stefansson et al., 2002]. DISC1 and NRG1 
have both important neurodevelopmental functions and have been extensively studied 
in the field of schizophrenia genetics [Chubb et al., 2008; Mei and Xiong, 2008]. 
Altered expression of genes involved in neuronal development and myelination have 
also been reported [Hakak et al., 2001]. 
 
Glutamate and neurodevelopment 
Glutamate receptors have an important role during neurodevelopment, with evidence 
of being critical for neuronal migration [Manent and Represa, 2007], corticogenesis 
[Furuta and Martin, 1999] and synaptogenesis [Yen et al., 1993], as examples. The 
three ionotropic glutamate receptor subtypes were shown to have distinct subunit 
binding patterns in cortical and subcortical regions during the second trimester [Lee 
and Choi, 1992], and in fetal cortex already in the first trimester [Ritter et al., 2001]. 
 
5.3 The main domains of neurodevelopment and plasticity 
in this thesis 
5.3.1 Neuronal migration 
Neuronal migration is the process where neurons move to their final destination in the 
cortex and other areas of the central nervous system. This movement occurs either 
through radial or tangential migration [Corbin et al., 2001]. None of the cortical 
neurons are generated within the cortex itself during cortical development, but instead 
pyramidal cells originate in the proliferative ventricular and subventricular zones, from 
where they migrate with radial glial cells leading their way [Rakic, 1988], and most 
interneurons move tangentially from the lateral ganglionic eminence of the ventral 
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forebrain [Rakic and Zecevic, 2003]. The six-layered neocortex is arranged in an 
inside-out manner, with the formation of inner layers first, and neurons destined to 
outer layers passing through those layers already formed [Rakic, 2002].  
 
Neuronal migration is dependent on extracellular signals which regulates cell 
movement, modulates the migrational speed, determines the direction of migration, 
and finally participates in ending migration when the proper position has been reached. 
The extracellular signals affect cell motility by regulating the cytoskeleton through 
intracellular signaling pathways, and cell adhesion molecules mediate cell-cell 
recognition and adhesion [Sobeih & Corfas, 2002]. The final position of the neuron 
affects its function, morphology, and formation of synaptic connections [Rakic, 1990]. 
Aberrant neuronal migration is suggested to be involved in the neurodevelopmental 
pathophysiology of schizophrenia, indicated from previously mentioned 
cytoarchitectural abnormalities found in brain tissue from schizophrenia patients. The 
reelin gene (RELN) is important for neuronal migration, and show decreased 
expression in several regions of the brain in tissue from schizophrenia patients 
compared with controls [Impagnatiello et al., 1998]. Also, DISC1 has been shown to 
be important for neuronal migration [Kamiya et al., 2005]. 
 
5.3.2 Perineuronal networks and the HNK-1 pathway 
In the adult brain, lattice-like extracellular matrix structures called Perineuronal Nets 
(PNs) are condensed around a subset of both inhibitory interneurons and excitatory 
neurons, and their proximal dendrites [Bruckner et al., 2000; Celio and Blumcke, 
1994; Viapiano and Matthews, 2006]. These net structures may regulate synaptic 
transmission and plasticity [Dityatev and Schachner, 2003] through their activity-
dependent deposition around successful synaptic connections [Dityatev et al., 2007; 
McRae et al., 2007], and inhibition of experience-dependent plasticity [Berardi et al., 
2004; Pizzorusso et al., 2002]. They could also potentially contribute to the synaptic 
overpruning suggested to occur in schizophrenia patients [Karlsgodt et al., 2008]. 
During neurodevelopment and in synaptic plasticity, carbohydrate-carrying molecules 
create diversity on cell surfaces and in the extracellular matrix, thereby mediating cell 
recognition [Kleene and Schachner, 2004]. The Human Natural Killer-1 (HNK-1) 
carbohydrate is among the most characteristic glycoepitopes in the nervous system, 
involved in neural crest cell migration, neurite outgrowth, neuronal cell adhesion, and 
synaptic plasticity [Kleene and Schachner, 2004; Morita et al., 2008]. One of the 
enzymes involved in the biosynthesis of HNK-1, Glucuronosyltransferase-P (GlcAT-
P) (encoded by beta-1,3-glucuronyltransferase 1, B3GAT1), has been suggested as a 
candidate gene for severe psychiatric phenotypes, including schizophrenia and 
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schizoaffective disorder, in a family study of a balanced chromosomal translocation 
[Jeffries et al., 2003]. 
 
5.4 Human genetics and disease mapping 
5.4.1 The human genome and genetic variation 
The first draft of the human genome sequence was announced in June 2000, and 
simultaneously published in February 2001, by the publicly funded Human Genome 
Project (HGP) [Lander et al., 2001] and the private company Celera Genomics [Venter 
et al., 2001]. A more comprehensive and high quality version of the human genome, 
including 99% of the gene-containing sequence, was made available in public 
databases (http://genome.ucsc.edu/; http://www.ncbi.nlm.nih.gov/) by HGP in spring 
2003 [Collins et al., 2003a; Collins et al., 2003b], fifty years after the discovery of the 
DNA structure [Watson and Crick, 1953]. These milestones formed the basis for a new 
era in the field of genetics research [Collins et al., 2003a], and one of the major 
challenges of the new millennium is to investigate on a larger scale how genetic 
variation contribute to complex disease. Even though humans share most of their DNA 
sequence, there are also millions of base pairs that differ between individuals.  
 
Human genome variants can be divided into two major classes, structural and single 
nucleotide variants, with the former including variation such as inversions, insertion-
deletions, and Copy Number Variants (CNVs) [Frazer et al., 2009]. A Minor Allele 
Frequency (MAF) of 1% defines a genetic variant as a polymorphism, in contrast to 
rare variants. Polymorphisms can be called common variants [Frazer et al., 2009], 
even though variants with a MAF above 5-10% are those often referred to as common 
[Owen et al., 2009]. The most prevalent variation in the human genome is the Single 
Nucleotide Polymorphism (SNP), with an estimated total number of about 11 million 
[Kruglyak and Nickerson, 2001]. In parallel with the public deposition of the first 
human draft sequence, a first systematic SNP Map became open source in the dbSNP 
Database, comprising of 1.4 million SNPs, mostly discovered by The SNP Consortium 
(TSC) and the HGP [Sachidanandam et al., 2001; Sherry et al., 2001]. Since then, SNP 
data mainly from TSC, the Perlegen SNP genotyping initiative and the HapMap 
project (described below) has been continuously added, and in 2006 the dbSNP 
contained almost 10.5 million human SNPs [Phillips, 2007]. 
A high number of studies have used SNPs in their quest for the genetic determinants in 
heritable complex or monogenic disorders, either by a direct or indirect approach. In 
the first, there is a hypothesis that the actual SNP is functional, for example by 
changing protein composition, transcription control or splicing pattern. Using the latter 
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approach, the SNPs investigated are chosen based on their property to capture 
surrounding SNP information, based on the correlation structure present in the 
genome.  
 
In all papers (I-IV) of this thesis, an indirect approach investigating the association 
between SNPs and psychiatric disease has been used. The two central concepts making 
this possible are Linkage Disequilibrium (LD), and tagSNPs. Information of the LD 
structure is assembled in the so called International HapMap Project, with the 
possibility to select tagSNPs as a project output. These three topics are described in 
detail below. 
 
5.4.2 Linkage disequilibrium 
Virtually all variable loci are caused by a single historical mutation event, which in the 
case of SNPs have increased in frequency to the level where the MAF ≥1% in the 
population. The new allele is surrounded by a distinct set of genetic variants present on 
the ancestral chromosome on which the mutation arose, and the set of alleles along the 
chromosome is called a haplotype. New haplotypes can form when new mutations or 
recombination events occur, and the coinheritance of SNP alleles of the same original 
haplotype is affected by the local recombination pattern. LD is the term for non-
random association of alleles at two or more loci, i.e. the situation when the frequency 
of certain combinations of alleles in a population differ from what would be expected 
if the alleles were randomly combined based on their frequencies. There are several 
LD measures that are all related to the quantity of D, which is calculated as: 
 
,D BAABAB PPP   
 
where DAB represents the difference in frequency of gametes carrying both allele A at 
one locus and allele B at another locus (PAB) and the product of the allele frequencies 
of A and B (PAPB). In the case of perfect linkage equilibrium the D measure will be 
equal to zero. Since D varies not only with the extent of LD, but also with the allele 
frequencies, the normalized D’ variable (0 ≤ D’ ≤ 1) was introduced [Lewontin, 1964]: 
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An additional common LD measure, the squared correlation coefficient r2 (0 ≤ r2 ≤ 1), 
incorporates the four allele frequencies when estimating LD between two SNPs [Hill 
and Robertson, 1968; Pritchard and Przeworski, 2001]:  
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The r2 measure is always equal to, or lower than, D’, and determines how well a locus 
can serve as a proxy for another locus. In a region with no historical recombination 
D’=1 between loci, while r2≤1, depending on the historical time points when the SNPs 
arose. When using LD in the search for disease causing loci the basis is that 
investigated markers are potentially linked to disease causing alleles on the same 
chromosome. LD is affected by factors such as recombination, mutation, changes in 
population size (especially population bottlenecks), genetic drift, and natural selection 
[Slatkin, 2008]. 
  
5.4.3 The international HapMap project and tag SNPs 
Because of the presence of LD, one can screen specific genes, chromosomal regions, 
or the whole genome, for disease causing loci, using non-redundant sets of so called 
tag SNPs, which serve as proxies for untyped correlated SNPs. To enable such large-
scale investigation of the contribution of common variation to phenotypic diversity, 
the International HapMap Project was initiated, with the goal to identify SNPs, 
investigate the pattern of LD, and make the data publicly available at their website 
(www.hapmap.org) [The et al., 2003; Thorisson et al., 2005]. 270 DNA samples from 
four geographically diverse populations were included: 30 trios (two parents and an 
adult child) from Utah, USA, with northern and western European ancestry (CEU), 
previously included in the Centre d’Etude du Polymorphisme Humain (CEPH) panel 
[Dausset et al., 1990], 90 Yoruba people in Ibadan, Nigeria (30 trios) (YRI), 45 
unrelated Japanese in Tokyo, Japan (JPT), and 45 unrelated Han Chinese in Beijing, 
China (CHB). About 1.2 million SNPs were successfully genotyped in Phase I of the 
project [The et al., 2005], and data analysis verified the generality of the previously 
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reported presence of recombination hotspots, long stretches of high LD, limited 
haplotype diversity, and widespread redundancy among nearby SNPs [Daly et al., 
2001; Gabriel et al., 2002]. Methods of picking tag SNPs was provided on the project 
website, of which the pairwise tagging option was used for all papers (I-IV) included 
in this thesis (discussed further in Material and Methods and Discussion sections). The 
HapMap data set has been steadily increasing (twelve data releases between June 2005 
and February 2009), with a total of over 3.1 million SNPs in Phase II [Frazer et al., 
2007], and 1.6 million SNPs genotyped in 1,115 samples from 11 populations in Phase 
III.  
 
5.5 Association study design 
The power and genetic resolution is greater in association studies, compared with 
linkage [Risch and Merikangas, 1996], making such design the more common choice 
when searching for genetic determinants of complex disease today. Association studies 
can be family- or population-based; the former mainly using trios (cases and their 
parents), and the latter using unrelated cases and controls [Laird and Lange, 2006]. In 
turn, population-based association studies can either be case-control or case-cohort 
studies; the former considering cases with a disease of interest and controls without 
this disease drawn from the same population, and the latter include cases and controls 
both sampled from a cohort study. Since the four association studies included in the 
present thesis are case-control association studies, such design will be the focus of this 
thesis. A protocol for a proper design of case-control association studies have been 
published in the Nature protocols journal [Zondervan and Cardon, 2007], and the 
important steps highlighted were: 
 
a) Define the phenotype in adequate detail 
b) Check the heritability of the disease of interest 
c) Consider whether a population-based study is suitable 
d) Select the controls appropriately 
e) Calculate the required sample size 
f) Consider whether it is a replication or de novo study 
 
In schizophrenia genetics, the first step (a) is not a trivial issue since the schizophrenia 
phenotype is defined according to a set of symptoms rather than using objective 
biological measures, as for e.g. Type 2 diabetes. The disease phenotype as well as 
other alternative phenotypes used in this thesis will be further described and discussed 
in the “Materials & Methods” and “Discussion” sections. Step (b) is already at hand 
24 
 
when studying schizophrenia, which has been shown to be a highly heritable disorder 
[Sullivan et al., 2003]. When considering step (c) regarding this thesis, the so called 
Common Disease-Common Variant (CDCV) hypothesis [Schork et al., 2009] was the 
basis for the design of Papers I-IV. We wanted to investigate if common variants of 
specific candidate genes were associated with the fairly common disorder 
schizophrenia, and the case-control design is in such a case appropriate. The selection 
of controls (d), as well as the power of our study with the used sample size (e), will be 
illuminated in the “Discussion” section. As for step (f), a true replication study should 
involve the genotyping of the exact same markers (or markers in high LD), in an 
ethnically similar population, as in the original study. The initial effect size needs to be 
properly assessed for appropriate power calculations. In the present thesis, most of the 
21 genes investigated are themselves de novo in the field of schizophrenia genetics, 
even though several have relations to other studied candidates, e.g. through biological 
interaction.  
 
One fundamental additional step in the design of association studies is the choice of 
the region of interest and subsequently the genetic markers, which is mentioned below. 
The above steps are equally important in all scenarios, from single markers, to 
candidate genes or the whole genome. 
 
5.5.1 Candidate genes or the whole genome? 
The region of interest in an association study can be single genetic variations, believed 
to exhibit a functional impact on disease [Fan et al., 2005], candidate genes (Paper I-
IV), chromosomal regions of interest implicated by linkage [Stefansson et al., 2002; 
Thomson et al., 2007] and cytogenetic studies [Callicott et al., 2005; Millar et al., 
2000], or the whole genome [O'Donovan et al., 2008]. The last is referred to as a 
Genome Wide Association Study (GWAS), a design which has become increasingly 
popular in parallel with decreasing genotyping costs. An advantage with GWAS is that 
you are able to screen the whole genome without being limited to predefined 
biological hypotheses. The same hypothesis-independent benefit is present when 
studying so called positional candidate genes, which have been highlighted because of 
its location in linkage regions, or in regions with chromosomal abnormalities which 
segregate with disease in families. This enables researchers to discover new biological 
mechanisms which might never otherwise have been suggested, based on current 
knowledge. However, GWAS are still not totally unbiased, because of the non-equal 
genome coverage of the genotyping chips, giving results which will be biased toward 
the best covered genes and regions. For six commonly used genotyping chips, the 
number of genes with 0% coverage (only considering genes with 5 HapMap common 
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SNPs), and global coverage, both given for the CEU population, ranged from 8-575 
genes and 64-93%, respectively [Li et al., 2008]. Depending on the genotyping success 
rate, the final coverage can be markedly lower than in theory [O'Donovan et al., 2008]. 
Therefore, candidate gene-based association studies are not yet outperformed by the 
GWASs, and are still an important complement for well-covered gene- or region-wide 
studies of potential susceptibility loci suggested based on solid hypotheses.  
 
5.6 Genetics and Schizophrenia 
5.6.1 A complex disorder with high heritability 
Adoption, twin and family studies of schizophrenia have consistently suggested an 
important genetic component [Owen, 2000], but the underlying biological mechanisms 
remain elusive. Schizophrenia is regarded as a complex disorder, where genetic 
variation as well as environmental effects are involved [Cowan et al., 2002; Hyman, 
2000]. The estimated heritability is approximately 80% [Cardno and Gottesman, 2000; 
Sullivan et al., 2003], clearly reflecting the importance of trying to elucidate which 
genes or other genetic loci are involved in causing schizophrenia. Even though it is 
apparent from genetic epidemiology that schizophrenia is a complex disease, the 
number of susceptibility loci, the extent of genetic heterogeneity, the disease risk 
conferred by each locus, and the degree of interaction among susceptibility loci are 
still unknown. A combination of common alleles with small effect and rare alleles with 
larger effects are probable [Owen et al., 2009] (Figure 1). 
 
 
Figure 1. An overview on the relationship between allele frequency, effect size, and the genetic 
studies available in common complex disease [modified after Owen et al., 2009]. 
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A high number of studies, and study designs, have been performed and published in 
the search for clues on schizophrenia aetiology, reflected by almost 6000 hits from a 
gross medical literature search on articles with “schizophrenia” in the title and 
including “genetics” (http://www.ncbi.nlm.nih.gov/sites/entrez, accessed 23rd of April 
2009). An overview of the main findings is given below. 
 
5.6.2 Linkage studies, positional candidates, chromosomal 
abnormalities 
By studying inheritance patterns in pedigrees, certain genome regions can be linked to 
a disease. If individuals with a disorder of interest inherit certain regions significantly 
more often than expected by chance, those are called linkage regions and might 
harbour susceptibility loci. A high number of linkage studies have been performed 
within the field of schizophrenia genetics, and even though the replication of these has 
been difficult, some potential regions of linkage have emerged [Owen et al., 2005]. 
Three promising candidate genes for schizophrenia, dysbindin (DTNBP1), NRG1, and 
D-amino oxidase activator (DAOA), were initially implicated after LD mapping across 
the linked regions 6p24-22, 8p21-22, and 13q34, respectively [Chumakov et al., 2002; 
Stefansson et al., 2002; Straub et al., 2002]. The three regions 8p, 22q, and 13q were 
suggestively linked with schizophrenia in a meta-analysis of genome-wide linkage 
scans, and the first two were highlighted as candidate linkage regions in a subsequent 
meta-analysis [Badner and Gershon, 2002; Lewis et al., 2003]. Recently, an extended 
version of the study by Lewis et al. (2003) was published, with almost three times 
more pedigrees, based on 32 independent genome-wide linkage scans [Ng et al., 
2008]. In the primary analysis, suggestive evidence for linkage was found on 
chromosomes 5q and 2q when including all genome scans, and 8p when including the 
22 European-ancestry scans only. A difficulty with linkage studies is that methods that 
are designed to detect a single major gene have been used. This may be a weak 
strategy for complex disorders, where family and linkage data suggest that multiple 
genes of small effect are much more likely [Risch, 2000]. However, even though 
single variants of weak effects are impossible to detect with linkage, the pooled effects 
of several rare or common copy number variants or SNPs, in a gene or chromosomal 
region, could produce linkage signals. In this aspect, linkage studies are flexible to 
allelic heterogeneity, and linkage regions suggested across several family sets might be 
of interest for in-depth studies [Holmans et al., 2009].  
 
By studying chromosomal abnormalities segregating with psychiatric disease in  
families, several potential susceptibility genes have emerged, such as DISC1 and  
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phosphodiesterase 4B (PDE4B) [Millar et al., 2004; Millar et al., 2005].  
   
5.6.3 Candidate based association studies 
Several reviews on the topic of candidate genes and schizophrenia are at hand, 
providing overviews of suggested susceptibility genes and their genetic evidence for 
being true causative genes [Harrison and Weinberger, 2005; Straub and Weinberger, 
2006; Williams et al., 2009]. A vast number of genetic association studies have been 
performed to elucidate the potential true involvement of genes of interest, and the field 
is hampered with inconsistent findings which are difficult to evaluate and interpret. 
For a constantly evolving overview of these schizophrenia genetic association studies, 
the SZGene database was created [Allen et al., 2008] (www.schizophreniaforum.org/ 
res/sczgene), providing a platform for navigation of studied candidate genes and a 
basis for systematic meta-analyses. The database included 1439 studies of 7094 
polymorphisms in 787 genes, and the gene in first place on the top results list was 
DISC1 (by 17th of May, 2009). Numerous association studies on DISC1 has been 
performed, one including the Scandinavian Collaboration on Psychiatric Etiology 
(SCOPE) sample used in this thesis [Saetre et al., 2008], and strong evidence for the 
involvement of DISC1 in schizophrenia etiology has emerged [Porteous et al., 2006]. 
 
The inconsistency in numerous association studies on schizophrenia may be due to 
both false positives and negatives, and true variability in associations across different 
populations. An important trend in association studies today is the progress from using 
small sample sizes (e.g. 200 cases & 200 controls), and the genotyping of a few 
markers, towards gene-wide genotyping of candidate regions using tagSNPs, in larger 
samples. Several collaborative efforts have evolved in order to achieve larger samples, 
e.g. the SGENE consortium (www.sgene.eu), and SCOPE, providing large multi-
center samples which are both used in this thesis. Through association analysis in ten 
independent case-control samples a SNP in the vicinity of the gene encoding fibroblast 
growth factor receptor 2 (FGFR2) was suggested as a potential susceptibility gene for 
schizophrenia [O'Donovan et al., 2009]. The first study to systematically select SNPs 
for LD-based gene-wide genotyping of the strong candidate gene NRG1, found a new 
gene region to be associated with schizophrenia [Thomson et al., 2007].  
 
5.6.4 Genome wide association studies (GWAS) 
It is estimated that approximately 16,000 genes are expressed in the brain [Insel and 
Collins, 2003], but only a fraction of these genes have been investigated so far. Instead 
of trying to choose candidates among this large brain-related gene pool, based on own 
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hypotheses limited by the current knowledge, GWAS has been introduced in the field 
of psychiatry. So far, six schizophrenia GWAS has been published, three based on 
DNA pooled samples and three on individual genotyping, without any findings 
reaching strict genome-wide significance (P=510-8) [Owen et al., 2009]. However, 
one of the studies investigated all hits below a threshold of P=510-5 in a second 
follow-up sample, and three out of twelve loci were associated with P<510-4 in the 
second run. The best hit from meta-analysis was a locus nearby a putative transcription 
regulator (zinc finger protein 804A, ZNF804A) (P=1.6110-7), and when including 
about 2,000 extra bipolar disorder samples the association was strengthened 
(P=9.9610-9) [O'Donovan et al., 2008]. One of the studies based on DNA pooling 
found suggestive evidence for a marker in RELN only in women. This female-specific 
effect was tested in four additional samples: the marker was nominally associated in 
one of the samples, with non-significant effects in the same direction in the other three, 
and a meta-analysis P=8.810-7 [Shifman et al., 2008].  
 
A large collaboration effort has been initiated, Psychiatric GWAS Consortium (PGC; 
http://pgc.unc.edu), with the aim to perform meta-analyses of GWAS for five 
psychiatric disorders (Attention Deficit Hyperactivity Disorder (ADHD), Autism, 
Bipolar disorder, Major depressive disorder, Schizophrenia) [PGC, 2009]. Eleven 
schizophrenia studies have been included, with a total of 9,588 cases and 13,500 
controls, as well as 650 trios. In a near future, PGC will be able to provide potentially 
revolutionizing new data for the community of psychiatric research. Whatever 
outcome is ahead, such large combined GWAS will be informative in how to proceed 
with future schizophrenia genetic studies, and will provide guidance when it comes to 
questions such as: is the common disease-common variant hypothesis valid and 
important for schizophrenia etiology? 
 
5.6.5 Studies of copy number variations (CNVs) 
It is now apparent that the presence of CNVs in the human genome is extensive 
[McCarroll et al., 2008]. CNVs have been associated with severe neurodevelopmental 
disorders such as autism [Sebat et al., 2007], and mental retardation [Sharp et al., 
2008]. The association between a 22q11.2 microdeletion and psychiatric disease has 
been reported since the 1990s, and the so called velo-cardio-facial syndrome (22q11.2 
deletion syndrome) is associated with a dramatically increased risk for schizophrenia 
[Bassett and Chow, 2008]. Recently, several publications have provided additional 
evidence for the involvement of CNVs in schizophrenia etiology. The total burden of 
duplications and deletions was shown to be markedly increased in schizophrenia 
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patients [International Schizophrenia Consortium, 2008; Walsh et al., 2008; Xu et al., 
2008]. CNVs within the neurexin 1 gene (NRXN1), has been independently reported in 
two affected siblings and their mother [Walsh et al., 2008], in identical twins 
concordant for childhood-onset schizophrenia [Kirov et al., 2008], to a higher extent in 
schizophrenia patients compared with controls in a large multicenter European case-
control sample [Rujescu et al., 2009], and in patients with autism [Szatmari et al., 
2007]. NRXN1 is a synaptic cell adhesion molecule, implicated in synaptogenesis. In 
addition, two large rare deletions (15q13.3 and 1q21.1) were independently shown to 
associate with schizophrenia, [International Schizophrenia Consortium, 2008; 
Stefansson et al., 2008], and mental retardation [Sharp et al., 2008]. Although the 
deletions were present in only 0.17% (15q13.3) and 0.23% (1q21.1) of the 
schizophrenia cases in the study by Stefansson et al., when compared with control 
frequencies, they conferred a highly increased risk for disease, with odds ratio (OR) of 
11.5 and 14.8, respectively [Stefansson et al., 2008]. 
 
5.6.6 Genetic studies using endophenotypes and clinical features 
Schizophrenia is a heterogeneous disorder, lacking characteristic biological markers or 
laboratory tests for diagnostics. One approach to assess a phenotype with a potentially 
closer and less complex link to specific underlying biological mechanisms, with 
presumably fewer genes involved, is to define so called endophenotypes (intermediate 
phenotypes). The endophenotype is a quantifiable trait, and five criteria have been 
suggested to be useful in the identification of such traits: the endophenotype should be 
heritable, associated with illness in the population, primarily state-independent, co-
segregating with illness in families, and found in nonaffected family members at a 
higher rate than in the general population [Gottesman and Gould, 2003]. The first step 
to find schizophrenia endophenotypes is commonly to study deficits which are 
associated with the disease, followed by heritability estimates [Braff et al., 2007]. Such 
an endophenotype could be neurophysiological, biochemical, endocrinological, 
neuroanatomical, cognitive, or neuropsychological. About six years ago, a large 
consortium was initiated, with the goal to investigate the occurrence and genetic 
architecture of quantitative endophenotypes associated with schizophrenia [Calkins et 
al., 2007]. The following endophenotypes, with reported deficits both in schizophrenia 
patients and their first-degree relatives, were included and subsequently shown to be 
heritable: three neurophysiological measures (P50 event-related potential suppression, 
prepulse inhibition of the startle response, and the antisaccade task for eye 
movements), as well as three neurocognitive measures (the Continuous Performance 
Test (CPT), the California Verbal Learning Test, second edition (CVLT-II) , and the 
Letter-Number-Sequencing test (LNS)) [Greenwood et al., 2007]. In addition, brain 
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morphometric abnormalities were suggested by others to be useful endophenotypes 
[Keshavan et al., 2007]. Studies of endophenotypes and genetic variation have 
reported associations, such as between DISC1 variation and both cognitive function 
[Porteous et al., 2006], and reduced prefrontal gray matter [Cannon et al., 2005], as 
well as for dopamine D2 receptor (DRD2) gene variants and working memory 
performance and brain activity in the prefrontal cortex and striatum [Bertolino et al., 
2009] 
 
Subtypes of schizophrenia defined by core symptoms or clinical characteristics, such 
as age at onset, has also been suggested to better represent the underlying genetic 
mechanisms [Fanous and Kendler, 2008]. The age of onset of psychosis in 
schizophrenia have recently been shown to be heritable [Hare et al., 2009], and age at 
onset was associated with Brain derived neurotrophic factor (BDNF) variants [Numata 
et al., 2006]. Based on symptom measures using the Positive and Negative Syndrome 
Scale (PANSS), a DTNBP1 haplotype was associated with hostility/excitement 
symptoms [Corvin et al., 2008], and a DAO SNP allele with depression/anxiety 
[Corvin et al., 2007]. DTNBP1 haplotypes were previously associated with negative 
symptoms using other rating scales [DeRosse et al., 2006; Fanous et al., 2005]. 
 
5.7 Genetic overlap of bipolar disorder and schizophrenia 
In current psychiatric diagnostic systems (DSM-IV and ICD-10), schizophrenia and 
bipolar disorder are treated as distinct disease entities, in line with the dichotomous 
classification by Emil Kraepelin from the early 19th century. Schizophrenia and bipolar 
disorder were divided into what he then called dementia praecox, and manic-
depressive insanity, respectively, but he later doubted this separation [Jablensky, 
1999]. Whether these disorders are in fact part of the same psychiatric continuum, with 
shared underlying biological mechanisms is currently debated [Craddock and Owen, 
2007; Crow, 2008]. Convincing evidence that bipolar disorder and schizophrenia have 
a partially shared genetic cause was recently presented in a large Swedish population-
based study [Lichtenstein et al., 2009]. Relatives of probands with bipolar disorder, 
including adopted away children of bipolar disorder biological parents, had an 
increased risk for schizophrenia. Common causative risk factors for schizophrenia and 
bipolar disorder has additionally been suggested based on other findings, such as 
potential endophenotype measures associated with both schizophrenia and bipolar 
disorder, e.g. reduced white matter densities [McIntosh et al., 2005; Sussmann et al., 
2009] and reduced anterior thalamic gray matter [McIntosh et al., 2004], common 
candidate susceptibility genes [Craddock et al., 2006], gene expression abnormalities 
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in post mortem brain tissue of both disorders [Guidotti et al., 2000], common 
epidemiological risk factors, e.g. winter/spring birth [Torrey, 1999], and similarities in 
cognitive impairment, especially in schizophrenia and psychotic bipolar disorder 
[Simonsen et al., 2009]. Recent evidence also suggests that antipsychotic drugs are 
effective in both disorders, and several atypical antipsychotics are now approved for 
bipolar disorder.  
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5.8 Aims of the study                  
The overall aim of this thesis was to gain more knowledge about the molecular genetic 
basis of schizophrenia, by performing case-control candidate gene-based studies using 
common SNP genotypes, and with special emphasis on genes important for 
neurodevelopmental processes, such as neuronal migration.   
Specifically, the aims were to: 
 
1) investigate if variants of 18 candidate genes involved in neuronal migration are 
associated with schizophrenia 
(Paper I)  
 
2) assess the potential involvement of DISC1interactor PDE4B in schizophrenia 
etiology, and a) test if there is a difference in association results between men 
and women as previously reported, b) investigate if variants of the PDE4B gene 
could be part of a genetic overlap with bipolar disorder susceptibility, c) 
investigate if PDE4B gene variants are associated with the extent of positive 
and negative symptoms in schizophrenia and bipolar disorder patients 
(Paper II) 
 
3) explore if variants of 10 key genes in the HNK-1 pathway and PNs are 
associated with schizophrenia, and a) study potential effects on age at onset and 
the extent of positive and negative symptoms in schizophrenia patients, as well 
as b) effects on learning and memory function, and IQ, in schizophrenia 
patients and controls 
(Paper III) 
 
4) Test the potential association between GRIK3 variants and schizophrenia, as 
well as with the extent of positive and negative symptoms 
(Paper IV) 
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6. Materials and methods 
6.1 Study samples 
 
The following three case-control samples have been used in this thesis: 
 SCOPE schizophrenia sample [≈ 850 cases & 1600 controls] 
Schizophrenia spectrum cases (schizophrenia, schizoaffective, and 
schizophreniform disorder) and controls from Norway, Sweden and Denmark. 
 
 SCOPE bipolar disorder sample [≈ 600 cases & 1400 controls] 
Bipolar disorder cases and controls from Norway and Denmark. 
 
 SGENE-plus sample [≈ 2,700 cases and 13,500 controls] 
Schizophrenia cases and controls from Iceland, Scotland, Germany, England, 
Italy, and Finland 
 
 
6.1.1 SCOPE schizophrenia sample description 
The SCOPE sample builds on and extends the Thematically Organized Psychoses 
(TOP) study in Norway, the Human Brain Informatics (HUBIN) study in Sweden, and 
the Danish Psychiatric Biobank in Denmark. The Norwegian and Danish studies are 
continuously including new patients and controls. 
 
Patients with schizophrenia, schizoaffective or schizophreniform disorder, and age 16-
65 years, are included in the TOP study, HUBIN and Danish Psychiatric Biobank, 
from the departments of the University Hospitals of Oslo, from psychiatric clinics in 
northwestern Stockholm County, and from the psychiatric departments at the six 
hospitals in the Copenhagen region, respectively. The Norwegian, Swedish, and 
Danish schizophrenia patients are diagnosed with the Structural Clinical Interview for 
DSM-IV (SCID), DSM-III-R/DSM-IV based on interviews and record reviews, or 
ICD-10, respectively. The protocol for the SCOPE studies is approved by the local 
Committees for Medical Research Ethics and the Data Inspectorates.  
 
The Norwegian sample  
The Norwegian patients had been recruited to the TOP study from all the psychiatric 
hospitals in the Oslo area, and clinically diagnosed with schizophrenia, 
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schizoaffective, or schizophreniform disorder. Two clinical professors continuously 
trained and supervised a group of research fellows in order to secure the quality of the 
clinical assessments. Reliability of the diagnosis has recently been tested, and the 
percentage of agreement was 82%, and Kappa 0.77 (95% CI: 0,60–0,94). 
 
The healthy Norwegian control subjects were randomly selected from the same 
catchment area as the patient groups, of Caucasian origin and born in Norway. 
Moreover, all participants had to have Norwegian as their first language or have 
received their compulsory schooling in Norway. The control subjects were screened by 
interview and with the Primary Care Evaluation of Mental Disorders (PRIME-MD). 
None of the control subjects had a history of moderate/severe head injury, neurological 
disorder, mental retardation or an age outside the range of 18-60 years. Healthy 
subjects were excluded if they or any of their close relatives had a lifetime history of a 
severe psychiatric disorder (schizophrenia, bipolar disorder and major depression), if 
themselves have a history of medical problems thought to interfere with brain function 
(hypothyroidism, uncontrolled hypertension and diabetes), or significant illicit drug 
use. 
 
The Danish sample  
All patients had been clinically diagnosed with schizophrenia (F20) or schizoaffective 
disorder (F25), without ever having received a diagnosis of mania or bipolar illness 
(F30-31). An experienced research- and consultant psychiatrist verified high reliability 
of the clinical diagnoses [Jakobsen et al., 2005] using Operational Criteria Checklist 
for Psychotic Illness and Affective Illness (OPCRIT) semi-structured interviews. The 
majority (85%) of the patients were ethnical Danish, i.e. the patients and both parents 
were born in Denmark, while in a minor fraction of the cases (15%) one parent was 
Caucasian and born outside Denmark in another North-western European country, 
primarily in Sweden or Norway, but also some in Germany, the Netherlands, England 
or France. 
 
The Danish controls were randomly selected out of a population of 15,000 blood 
donors from the Danish Blood Donor Corps in the Copenhagen area, which includes 
>5% of the Danish population who donate blood on a voluntary and unpaid basis. 
Apparent behavioral abnormality was an exclusion criterion and all individuals stated 
that they felt completely healthy with a possibility to discuss any health related issues 
with a physician. Two unrelated healthy control subjects of Danish Caucasian origin 
were matched to each patient on gender, year of birth and month of birth, with 
matching ethnicity. 
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The Swedish sample  
Swedish patients had been recruited from psychiatric clinics in northwestern 
Stockholm County, and clinically diagnosed with schizophrenia, schizoaffective, or 
schizophreniform disorder. All patients were Caucasian. Based on the birth country of 
the grandparents or greater grandparents, 79%, 12% and 9% of the patients were 
estimated to be of Swedish, Finnish or other European origin, respectively. 
 
The Swedish control subjects were recruited among subjects previous participating in 
biological psychiatric research at the Karolinska Institute or drawn from a 
representative register of the population in Stockholm County. All controls were 
Caucasian and 86%, 6%, and 8% were estimated to be of Swedish, Finnish or other 
European origin, respectively. The mean age was 40.5 (+/−9.8) years when entering 
the study. None of the controls suffered from schizophrenia. 
 
 
6.1.2 SCOPE bipolar disorder sample description 
The Norwegian sample  
The Norwegian bipolar disorder patients were recruited to the TOP study as the 
schizophrenia patients, and were diagnosed with bipolar disorder type I, bipolar 
disorder type II, and bipolar disorder not otherwise specified, according to DSM-IV 
using SCID. 
 
The criteria for inclusion of the control subjects are the same as stated above for the 
Norwegian controls in the SCOPE sample. A subset (n=152) of the controls in the 
bipolar sample in Paper II, are overlapping with controls in the schizophrenia case-
control sample.  
 
The Danish sample 
The Danish patients had been included all over Denmark (1996-1998), or in the 
Copenhagen area by the Danish Psychiatric Biobank (2002-2007). The first patient 
group had been diagnosed with Schedules for Clinical Assessment in Neuropsychiatry 
(SCAN) [Wing et al., 1998] interviews fulfilling a best estimate diagnosis of bipolar 
affective disorder and BPI, according to the ICD-10-DCR [WHO, 1993] and the DSM-
IV, respectively. The latter group was clinically diagnosed with bipolar affective 
disorder according to ICD-10-DCR.  
 
The Danish controls were distinct from those in the schizophrenia case-control sample, 
but recruited as previously described above, or included as selected controls screened 
for psychiatric disease in a previous study [Mellerup et al., 2001].  
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6.1.3 SGENE-plus sample description 
Genotypes of SNPs serving as proxies for six tagSNPs genotyped in SCOPE in Paper 
III, were drawn from a genome-wide data set of a multi-national European sample. 
This replication sample included 1,321 patients affected with schizophrenia and 
12,277 control individuals from Iceland, Scotland, Germany, England, Italy, and 
Finland (the SGENE sample, www.SGENE.eu); as well as 1,342 schizophrenia 
patients and 1,221 control individuals from Scotland and Germany (the SGENE-plus 
sample).  Ethical approval was obtained from the local Ethical Committees. All 
participants have given written informed consent prior to inclusion into the project. 
 
 
6.1.4 Clinical features and endophenotypes in the TOP study 
At the time of inclusion, Norwegian patients’ symptoms are assessed using a number 
of different tests, such as the PANSS. At a later occasion the neurocognitive 
performance of both patients and controls is measured with a comprehensive test 
battery (see below). In Paper II and IV, we searched for susceptibility-modifier 
variants in PDE4B and GRIK3, respectively, for association with PANSS positive and 
negative sum scores. In Paper III we included neurocognitive measures of learning 
and memory, as well as IQ, in addition to PANSS scores and age at onset, and 
searched for both susceptibility-modifier and pure modifier variants, based on all 
tagSNPs in the three genes of the HNK-1 pathway, including B3GAT2. 
 
Neurocognitive tests 
A unit for neurocognitive testing is established in the TOP group in collaboration with  
the Institute of Psychology, UiO (Prof. K. Sundet), and all Norwegian patients go 
through the following tests: Grooved Pegboard (Motor function), Coding/Trail Making 
(Psychomotoric tempo), Number memory (Attention), Paced Auditory Serial Addition 
Task (PASAT) (Working Memory), CVLT-II (Executive function), Wechsler 
Abbreviated Scale of Intelligence (WASI), National Adult Reading Test (NART) 
(Premorbid level). In the follow-up study, the following tests are also included: CPT 
(Attention /Vigilance), N-Back (Working Memory), Continous Visual Memory Test 
(CVMT), Wisconsin Card Sorting Test (WCST) (Executive function), Face/Voice 
Emotion (Social cognition), Assessment of Interpersonal Problem Solving Skills 
(AIPSS), WCST +/- help (Learning potential), The Social Functioning Scale (Daily 
Life function).  
 
Positive and negative syndrome scale (PANSS) 
PANSS is an instrument for measurement of the severity of symptoms, based on 30 
psychiatric parameters, which are part of a positive scale (delusions, conceptual 
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disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness, 
hostility), a negative scale (blunted affect, emotional withdrawal, poor rapport, 
passive-apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity 
& flow of conversation, stereotyped thinking), and the 16 remaining items are part of a 
general psychopathology scale. For each parameter the minimum and maximum scores 
are 1 and 7, respectively (1=absent, 2=minimal, 3=mild, 4=moderate, 5=moderate-
severe, 6=severe, and 7=extreme), which means that the potential ranges for the 
positive and negative symptom scales are 7-49 each.  
 
At the time of inclusion, the patients’ symptoms are assessed with PANSS scores, 
reflecting the status during the last week before inclusion in the TOP study. All raters 
participated in a structured training course, and reliability was measured based on 
videotaped actual case interviews. Inter-rater reliability was good, with an intra-class 
correlation coefficient (1.1) of 0.73, 0.73 and 0.71 for PANSS positive, negative and 
general subscales, respectively. 
 
 
6.1.5 Genetic features of the TOP sample 
Based on GWAS data from the Affymetrix Genome-Wide Human SNP Array 6.0 on 
the Norwegian TOP sample [Athanasiu et al., manuscript], the overall genetic structure 
for this sample has been compared with HapMap samples representing ten different 
populations (Figure 2). Norwegians cluster mainly with the CEU sample, comprised of 
Americans with north-western European ancestry. When visualizing the Norwegian 
TOP data set alone, to compare the schizophrenia spectrum and bipolar disorder 
patients, as well as controls, it is evident that the three groups are very similar in the 
overall genetic structure (Figure 3). The TOP dataset in Figure 2 and 3 contain 747 
samples, including 89% of the Norwegian schizophrenia data sets used in Paper I, II, 
IV, and 83% of the data set in Paper III. 
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Figure 2. Multidimensional scaling (MDS) based on 535,000 SNPs genotyped in the Norwegian TOP 
sample (n=747) and ten separate HapMap samples. On top, the first component (x-axis) is plotted 
against the second (y-axis), and below, the first component (x-axis) is plotted against the third (y-axis). 
TOP QC1: TOP sample after main quality control; ASW: African ancestry in Southwest USA; CEU: 
Utah residents with Northern and Western European ancestry from the CEPH collection; CHB: Han 
Chinese in Beijing, China; GIH: Gujarati Indians in Houston, Texas; JPT: Japanese in Tokyo, Japan; 
LWK: Luhya in Webuye, Kenya; MEX: Mexican ancestry in Los Angeles, California; MKK: Maasai 
in Kinyawa, Kenya; TSI: Toscans in Italy; YRI: Yoruban in Ibadan, Nigeria.  
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Figure 3. Principal components analysis (PCA) on 535,000 SNPs genotyped in the Norwegian TOP 
sample (n=747), including schizophrenia spectrum patients, bipolar patients, and controls. Principal 
component 2 (PCA2, x-axis) is plotted against principal component 1 (PCA1, y-axis), showing a 
complete overlap between the three groups. This overlap is similar in the corresponding PCA1-PCA3 
plot (not shown). 
 
6.2 The candidate genes studied 
In total, 30 genes have been investigated in Paper I-IV. An overview of all genes, 
with their chromosomal localization, is shown in Table 1. Genes involved in the 
process of neuronal migration, the formation of perineuronal nets during brain 
maturation, the HNK-1 biosynthesis, and glutamate signaling were included, some of 
which had been associated with schizophrenia previously. PDE4B was included 
mainly because of its direct interaction with DISC1, which regulates its cAMP 
hydrolysis function, and the gene was also independently associated with increased 
risk for schizophrenia in a family with a balanced translocation [Millar et al., 2005]. 
Several of the genes encode proteins that interact with DISC1 directly (PAFAH1B1 
[LIS1], NDEL1, YWHAE) [Camargo et al., 2007], or with a DISC1 interactor (CDK5, 
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CDK5R, MAP1B, CDC42) [Jimenez-Mateos et al., 2005; Kholmanskikh et al., 2006; 
Niethammer et al., 2000]. 
  Table 1. The candidate genes. 
Gene Symbol Chromosomal Position Biological Process of Interest 
ASTN1 1q25.2 Neuronal migration – adhesion 
MDGA1 6p21.2 Neuronal migration – adhesion 
SPARCL1 4q22-q25 Neuronal migration – adhesion 
ITGA3 17q21.33 Neuronal migration - adhesion & motility 
RELN 7q22.1 Neuronal migration - adhesion & motility 
CDC42 1p36.12 Neuronal migration – motility 
CDK5 7q36 Neuronal migration – motility 
CDK5R1 17q12 Neuronal migration – motility 
ENAH 1q42.12 Neuronal migration – motility 
EVL 14q32.32 Neuronal migration – motility 
FILIP1 6q14.1 Neuronal migration – motility 
MAP1B 5q13.2 Neuronal migration – motility 
NDEL1 17p13.1 Neuronal migration – motility 
PAFAH1B1 (LIS1) 17p13.3 Neuronal migration – motility 
VASP 19q13.2-13.3 Neuronal migration – motility 
YWHAE 17p13.3 Neuronal migration – motility 
DLX1 2q31.1 Neuronal migration - transcription 
PAX6 11p13 Neuronal migration - transcription 
PDE4B 1p31 cAMP signalling 
BCAN 1q31 Perineuronal net formation 
HAPLN1 5q14.3 Perineuronal net formation 
HAPLN2 1q23.1 Perineuronal net formation 
HAPLN3 15q26.1 Perineuronal net formation 
HAPLN4 19p13.1 Perineuronal net formation 
NCAN 19p12 Perineuronal net formation 
TNR 1q24 Perineuronal net formation 
B3GAT1 11q25 HNK-1 biosynthesis 
B3GAT2 6q13 HNK-1 biosynthesis 
CHST10 2q11.2 HNK-1 biosynthesis 
GRIK3 1p34-33 Glutamate signalling 
 
 
6.3 Genotyping technologies 
The SNPlex™ Genotyping System  
Thirty-one tagSNPs in six of the genes in Paper I, as well as 103 tagSNPs in the ten 
genes of Paper III, were genotyped with the 48-plex SNPlex technology (Applied 
Biosystems, Foster City, CA, USA), at the Department of Medical Genetics (Oslo 
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University Hospital-Ulleval, Oslo, Norway). The assay was performed in a 384-plate 
format, with four equal control CEPH-samples and four buffer samples on each plate, 
in addition to eight positive and eight negative controls included in the SNPlex kit. All 
pipetting steps were performed using Biomek Fx robots (Beckman Coulter Inc., 
Fullerton, CA, USA). DNA concentration was measured with the Quant-iT DNA 
Assay Kit (Invitrogen Corporation, Carlsbad, CA, USA), and diluted to around 40 
ng/μl. In the first step, 3 μl of genomic DNA was dispensed into a chilled 384-well 
plate and placed in a thermal cycler for fragmentation, 1 minute at 4°C, 5 minutes at 
99°C, followed by cooling to 4°C. The SNPlex oligonucleotide ligation assay (OLA) 
reaction mix was prepared, composed of allele- and locus-specific probes, universal 
linkers, enzymes promoting 5’-end phosphorylation of probes and linkers, as well as 
ligase for ligation with the genomic DNA. 3 μl was added to the 384-well plate with 
DNA, and the ligation reaction was run using a thermal cycler. The subsequent steps 
were performed according to the protocol provided by the manufacturer (Applied 
Biosystems). In brief, first, the ligation products from the previous step were purified 
using two exonucleases to digest parts of the ligated reaction products, unligated 
oligonucleotides and genomic DNA. Second, the purified ligation product was PCR 
amplified, the biotinylated PCR product were bound to streptavidin covered plate 
wells   Allele calling was performed automatically using the GeneMapper software 4.0 
(Applied Biosystems), with 384 samples clustered simultaneously using the “Rules” 
clustering algorithm. The automatic allele calling was manually evaluated, and 
samples appearing among negative control samples in the polar plots were excluded 
from further analyses.    
 
The GoldenGate® Assay 
Two hundred fifty-eight tagSNPs in 12 of the genes in Paper I,  40 and 72 PDE4B 
tagSNPs in the schizophrenia and bipolar disorder sample of Paper II, respectively, as 
well as the 30 GRIK3 tagSNPs of Paper IV, were genotyped with the 1536-plex 
GoldenGate assay (Illumina, Inc., San Diego, CA) on Illumina BeadStation 500GX at 
the SNP Technology Platform, Uppsala University, Sweden (www.genotyping.se), 
accredited by the Swedish accreditation agency SWEDAC, and approved according to 
a quality system based on the international SS-EN ISO/IEC 17025 standard.   
 
The TaqMan® SNP Genotyping Assay 
Six tagSNPs (Paper III) were genotyped by the single-plex Taqman assay (Applied 
Biosystems, Foster City, CA, USA), because they failed to be genotyped by the 
SNPlex technology. The genotyping was performed at the Department of Medical 
Genetics (Oslo University Hospital-Ulleval, Oslo, Norway). 
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6.4 Statistics 
6.4.1 Statistical tests and methods 
Hardy Weinberg equilibrium 
The exact χ2 test was used to test for departure from Hardy Weinberg Equilibrium 
(HWE) in controls. In Paper I, we corrected the significance threshold with the 
number of genes tested (P=0.05/18=0.0028), being conservative but at the same time 
taking into account the high number of genes tested. In Paper IV, with only one gene 
tested, we used the uncorrected nominal threshold of 0.05 as exclusion criteria. In 
Paper II and III, the default threshold 0.001, in the software PLINK, was used. 
 
The fixation index 
To estimate the genetic heterogeneity between the three Scandinavian samples, we 
calculated the overall fixation index, FST, using the controls. An FST was calculated for 
each gene with at least three SNPs genotyped, and then the weighted mean over all 
gene-based FST was the overall FST, with the SNP number in each gene used as 
weights. 
 
Standard and stratified singlemarker association tests 
The most common test for genetic association is the standard χ2 test, based on a 2 x 2 
(Table 2) or 2 x 3 (Table 3) table, depending on if testing for independence of the 
phenotype from alleles or genotypes, respectively. The null hypothesis of no 
association is rejected if the χ2 test statistic is large enough. 
 
Table 2. 2 x 2 contingency table for SNP alleles.  
Allele   A a Total 
Frequency/ Cases  A1 A2 Atot 
Allele 
count Controls C1 C2 Ctot 
  Total A a N 
 
Table 3. 2 x 3 contingency table for SNP genotypes. 
Genotype   AA Aa aa Total 
Frequency/ Cases  A1 A2 A3 Atot 
Allele 
count Controls C1 C2 C3 Ctot 
  Total AA Aa aa N 
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The allele-based test statistic is calculated as follows (with each included factor given 
in Table 2):  
 
aACtotAtot
CACANallele



2
2 )2112(

 
 
When using the standard χ2 test to compare genotype frequencies between cases and 
controls, the observed frequencies are compared with those expected under the null 
hypothesis. The test statistic is calculated as follows (with each included factor given 
in Table 3): 
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In the present thesis, three multi-national case-control samples were used, combining 
several independent subsamples, from three Scandinavian countries (Paper I-IV), as 
well as the SGENE-plus North-European countries (Paper III). In all initial 
association tests, the covariate “sample origin” has been included, to correct for 
potential differences between the independent subsamples. Standard χ2-tests were used 
to compare effects sizes between the separate subsamples (Paper I, II, IV).   
  
A commonly used statistical method for stratified association analysis is the Cochran-
Mantel-Haenszel (CMH) χ2 test for independence of i x j x k contingency tables, where 
k is the number of strata (=number of subsamples in this case). We used both allele-
based 2 x 2 x k (Paper I, III, IV), and genotype-based 2 x 3 x k (Paper I, IV) tests. 
To evaluate the effect size of the potential risk conferred by a certain genetic marker 
studied, the OR is the statistic conventionally calculated. For a SNP with alleles A and 
a, the OR is the ratio between the odds of being a case when having the A allele and 
the odds of being a case when having the a allele. More specifically, for a 2 x 2 
contingency table (Table 2), where A1, A2, C1, and C2 are the allele frequencies or 
allele counts, the OR=(A1/C1)/(A2/C2)=A1∙C2/C1∙A2. The OR is thus calculated by 
comparing the allele frequencies between cases and controls for each of the two 
alleles. The squared OR is also the numerator in the allele-based χ2 test statistic 
calculation. To determine the uncertainty of the calculated risk measure, a 95% 
confidence interval is commonly accompanying the OR. The Breslow day test (BD) 
measures the heterogeneity of the ORs between strata defined in the CMH test, which 
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in our case are groups based on “sample origin” (Paper I, III, IV), or gender (Paper 
IV). In Paper II, the software UNPHASED (described below) were used for both 
allele- and genotype-based single marker, as well as haplotype, analysis. The software 
uses a retrospective likelihood, and to account for possible population stratification, 
we included country of origin as a confounder factor in the analysis.  
 
To test an additive model, with the covariate sample origin, we used logistic regression 
in Paper III. In this paper, the non-stratified trend and standard χ2 tests were 
performed, with the only intention to compare with the stratified results and not to find 
potential new associations. When investigating the effects of SNP genotypes on 
cognitive raw test scores and IQ in the same paper, linear regression analysis, with age 
and sex as covariates, was used. Three inheritance models: additive, recessive, and 
dominant, were tested for. For SNPs nominally associated for the same measure in 
both cases and controls, the interaction between case control status and genotypic 
effect on the phenotype was investigated.  
 
The effect of genotypes on PANSS positive and negative sum scores were assessed 
using non-parametric Kruskal Wallis (Paper II and III) and Mann-Whitney tests 
(Paper III), the first including the three genotypes for each tagSNP as grouping 
variable, and the latter was performed after re-coding of the genotypes into two 
groups, according to a recessive or a dominant inheritance model. In Paper IV, the 
PANSS scores were tested for association with tagSNPs through independent sample 
t-tests (Paper IV).  
 
Survival analysis with the Cox proportional hazards regression model, with sex and 
country of origin as covariates, was used to investigate the effects of genotype on 
AAO. The difference of each of the three genotypes, as well as dominant and recessive 
inheritance models, was tested for.           
 
Haplotype block estimation and haplotype analysis 
Through-out the genome, there are regions of high and low LD, and segments with 
high LD are referred to as LD blocks, within which there is limited haplotype diversity 
[Patil et al., 2001]. In Paper I, we estimated haplotype blocks using the method by 
Gabriel et al. [Gabriel et al., 2002], implemented in Haploview. The estimation was 
based on the genotyped tagSNPs in our sample, which might be limited. As 
comparison, I have now retrospectively used the MDGA1 genotypes for the HapMap 
CEU sample, and estimated LD blocks based on the solid spine method implemented 
in Haploview  (D’>0.8) (as in Paper III), and by joining adjacent blocks when 
multiallelic D’>0.95. The estimated LD blocks are the same as previously, with the 
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exception of the most 5’ block analyzed for haplotype association, which was 
increased in size including also the first seven 5’ tagSNPs. In Paper II, the solid spine 
block estimation was used based on the tagSNP genotypes in the bipolar disorder 
sample. 
 
Potentially, combinations of tagSNPs into haplotypes might better pick up association 
signals, if a disease variant is in stronger LD with a certain haplotype than with any 
single tagSNP. For all papers, haplotype analysis was performed using the software 
UNPHASED, testing for both global and individual haplotype associations including 
sample origin as a confounder. In Paper I, all 2-4 marker combinations within all 
estimated blocks harboring tagSNPs with a P≤0.1 from single markers tests, were 
tested for association with schizophrenia. In Paper II and IV, the whole gene regions 
were assessed testing 2-, 3-, and 4-marker sliding windows for association. In Paper 
III, the haplotype analysis was restricted to one haplotype block, including three 
tagSNPs nominally associated in the initial analysis, as well as a forth tagSNP. All 2-4 
combinations were tested for association.   
 
Correction for multiple testing 
In Paper I and IV, a so called Nyholt-corrected threshold was presented [Nyholt, 
2004], for the single SNP association tests, which implements the LD structure 
between the markers tested, to take into account their potential non-independency, in 
order to estimate the number of independent tests. Using this estimated number, a 
regular Bonferroni correction can be applied. In the thesis papers we used the 
recommended better estimate of the effective number of markers [Li and Ji, 2005]. 
Permutation-based correction was used for the single SNP tests in Paper II and III, as 
well as for all haplotype analyses, shuffling the case control status 1,000-100,000 
times. For the haplotype analyses the permutations were performed separately for each 
sliding window (Paper II and IV), for each specific single marker combination chosen 
based on the best initial single marker results (Paper I and IV), within each of the 
separate blocks tested (Paper I and III), and for each of the 2-4 windows within 
blocks with more than 4 markers (Paper I). A non-combined permutation-correction 
might not be ideal, but on the other hand, a lot of non-independent tests were included 
in the haplotype analyses.   
 
 
6.4.2 The statistical softwares 
All of the softwares used in this thesis, except for SPSS, are open-source tools and free 
to download at their respective web pages. 
46 
 
PLINK 
PLINK is a toolset designed for whole genome genetic association analysis 
(pngu.mgh.harvard.edu/purcell/plink/) [Purcell et al., 2007], and the Windows/ 
MSDOS command line application was utilized for single marker association analysis 
in three of the papers (Paper I, III, IV), and for the HWE test in two papers (Paper 
III, IV), using versions 0.99q (Paper I, IV), 1.04 (Paper II), and 1.05 (Paper III). 
 
Unphased 
UNPHASED is an application for performing genetic association analysis, which 
implements maximum-likelihood inference of haplotypes and genetic effects while 
allowing for uncertain phase and missing genotypes (www.mrc-
bsu.cam.ac.uk/personal/ frank/software /unphased) [Dudbridge, 2008]. The graphical 
user interface (GUI) of UNPHASED was used in all four papers for haplotype 
analysis, and also single marker association tests in Paper II. It was run locally or at 
the University of Oslo Bioportal (www.bioportal.uio.no/), the latter being a web-based 
service platform providing access to a large computational cluster, using versions 3.0.8 
and 3.0.9 (Paper I), 3.0.10 (Paper IV), and 3.0.13 (Paper II, III). 
 
Haploview 
Haploview is an analysis platform that was used for calculation and visualization of 
LD, as well as haplotype block estimation, in the present thesis (www.broad.mit.edu/ 
haploview/haploview) [Barrett et al., 2005]. The GUI for Windows of versions 3.32 
(Paper I, IV), and 4.1 (Paper II, III) was used.  
R 
The R platform is a software environment for statistical computing and graphics 
(www.r-project.org/), which was used for data management, as well as genotype-based 
single marker association tests and the exact HWE test implemented in the Genetics 
package (Paper I, IV). 
 
Arlequin 
The software Arlequin is a GUI-based tool for population genetics data analysis that 
was used to calculate the Fixation index, FST, in all four papers, using version 3.1 
(cmpg.unibe.ch/software/arlequin3/) [Excoffier et al., 2005].  
 
Single Nucleotide Polymorphism Spectral Decomposition (SNPSpD) 
The software SNPSpD is a web-based tool (gump.qimr.edu.au/general/daleN/ 
SNPSpD) implemented by D. Nyholt [Nyholt, 2004] for a multiple testing correction 
method. The effective number of markers, Meff, taking into account the LD structure 
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between markers, can be estimated, as well as the recommended more accurate 
estimation, MeffLi [Li and Ji, 2005]. 
 
SPSS 
One of the products from SPSS Inc. (www.spss.com/) is the statistical program SPSS 
Statistics (renamed into Predictive Analytics Software (PASW) Statistics), which was 
used for the PANSS analyses. 
 
 
  
7. Summary of results 
All four papers included in this thesis are candidate gene-based association studies of 
schizophrenia, investigating 18 (Paper I), one (Paper II), 10 (Paper III), and one 
(Paper IV) gene(s). In each paper the markers have been chosen using pair-wise 
tagging, with the aim of covering most of the known common variation in the genes. 
In Paper II, tagSNPs were also genotyped in bipolar disorder patients. The results of 
each paper are summarized below.  
In the sections below, schizophrenia spectrum cases, including patients diagnosed with 
schizophrenia, schizoaffective disorder, and schizophreniform disorder, are referred to 
as “schizophrenia”. Patient groups with solely the schizophrenia diagnosis are referred 
to as “strict schizophrenia”. In all combined analyses of the three Scandinavian 
samples, the sample origin is included as a covariate. 
Paper I: Association analysis of schizophrenia on 18 genes involved in neuronal 
migration: MDGA1 as a new susceptibility gene.                    
 
To investigate if tagSNPs in the candidate genes are associated with schizophrenia, we 
used a sample of 839 schizophrenia cases + 1,473 controls for 12 genes, and 758 
schizophrenia cases + 1,293 controls for 6 genes. The difference in numbers is due to 
the use of two separate genotyping occasions as well as methods. The overall fixation 
index FST was 0.00071 based on the Norwegian, Danish and Swedish control 
populations, indicating general allele frequency homogeneity between samples. The 
final coverage of common HapMap SNPs by the genotyped tagSNPs (r2≥0.8; 
MAF≥5%; MAF≥20% for RELN), using an updated HapMap data release (Data Rel 
Jan07), was ≥90% for 11 genes, between 64 and 84% for 6 genes, and only 25% for 
CDK5. Twenty tagSNPs (out of 289, 6.9%) located in six genes, attained nominal 
significant P-values (P≤0.05) in genotypic and/or allelic association tests, when 
comparing schizophrenia cases with controls. When using strict schizophrenia in the 
follow-up analysis of these 20 tagSNPs, 15 were still nominally significant, despite the 
reduction in case sample size with over 12%. The stongest association was found for 
tagSNP rs9462341, located in MDGA1 (schizophrenia: Pgenotypic=0.00095, 
Pallelic=0.010; strict schizophrenia: Pgenotypic=0.00068, Pallelic=0.0054), together with five 
other nominally associated tagSNPs (17% of the MDGA1 tagSNPs). The ORs for 
those five MDGA1 tagSNPs nominally associated in the allelic test were calculated in 
the combined and three Scandinavian sample(s) separately, showing a risk effect for 
the same allele in all groups tested. Nine of the RELN tagSNPs (13%) were nominally 
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associated, five in both genotypic and allelic tests, and two out of six OR calculations 
showing a risk effect for the same allele in all groups tested. Two out of the three 
DLX1 tagSNPs assessed were nominally associated in the genotypic test. One out of 
the eight ITGA3 tagSNPs assessed was nominally associated in the allelic test, as well 
as in the genotypic test for strict schizophrenia only. The same ITGA3 tagSNP allele 
conferred a risk effect in the combined as well as the three separate samples. The one 
ASTN1 and SPARCL1 tagSNP nominally associated, had PHWE=0.014 and PBD=0.05, 
respectively. The best finding was above the Nyholt-corrected significance threshold 
of P=0.00027, and no association tests with 2- to 4-marker haplotypes achieved higher 
significance levels. 
 
To note: For one of the 21 tagSNPs given in the Table III of Paper I, there was only 
three minor control homozygotes present, and since it was only nominally associated 
in the genotype test this result was not reliable. It is therefore not included in the 
mentioned result figures above. 
 
Paper II: Association study of PDE4B Gene Variants in Scandinavian Schizophrenia 
and Bipolar Disorder multicenter case-control samples 
  
To assess the potential involvement of DISC1 interactor PDE4B in schizophrenia and 
bipolar etiology, we examined the PDE4B gene in a sample of 837 schizophrenia cases 
+ 1,473 controls, as well as 594 bipolar disorder cases + 1,421 partly overlapping 
(10.7%) controls. Forty and 72 tagSNPs were genotyped and statistically analyzed in 
the former and latter sample, respectively, with the 40 giving a final coverage of 86% 
(r2≥0.8, MAF≥20%, 318 HapMap SNPs in total), and the 72 a final coverage of 92% 
(r2≥0.8, MAF≥5%, 449 HapMap SNPs in total). The gene-based FSTs were 0.00004 
and -0.00008 for PDE4B, in the comparison of the Norwegian, Danish, and Swedish 
controls in the schizophrenia sample, and the Norwegian and Danish controls in the 
bipolar disorder sample, respectively. No association findings were statistically 
significant after correction for multiple testing (Best P 0.17), but hypothesis-
generating nominal associations (P≤0.05) are summarized.  
 
Two independent tagSNPs (r2 = 0.04) were nominally associated with schizophrenia, 
and with ORs≥1 for the major allele in the combined, as well as separate Norwegian, 
Danish, and Swedish sample. When genders were analyzed separately, there were 
nominally significant associations only in females, between four tagSNPs and 
schizophrenia. The major alleles and major allele homozygotes had OR≥1 in the 
combined (OR: 1.18-1.48), as well as separate Norwegian, Danish, and Swedish 
sample. 
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Eleven tagSNPs were nominally associated with bipolar disorder, two of which are in 
complete LD (r2 = 1.0). The same allele had OR≥1 in the combined, as well as 
separate Norwegian, Danish, and Swedish sample. For the tagSNP with the strongest 
association, the best fitting model was recessive (homozygote minor allele: 
OR(95%CI) = 4.43(1.78-11.02), P = 0.00052). The gender-specific associations were 
not as consistent as for schizophrenia, with tagSNPs being nominally associated with 
both females (two) and males (three).  
 
All of the six nominally associated tagSNPs in the schizophrenia sample have either 
been genotyped themselves or by proxies in the bipolar disorder sample. Two of the 
proxies for tagSNPs nominally associated in women, were nominally associated with 
bipolar disorder in the total sample. All four tagSNPs were present in a 48 kb region 
spanning the PDE4B3 splice site. However, increased risk for schizophrenia was 
associated with being homozygous for the major alleles, while in contrast the 
homozygotes for the minor alleles displayed increased risk for bipolar disorder. 
 
The potential association between tagSNPs and positive and negative symptom sum 
scores were tested in Norwegian schizophrenia (n=153; five tests) and bipolar disorder 
(n=128; twelve tests) patients. One schizophrenia tagSNP was associated with positive 
symptoms in the total sample (P = 0.003), and all of the three tagSNPs that were 
analyzed in females were associated with positive symptoms (0.001 P  0.004). Two 
of those three tagSNPs have proxies in the bipolar disorder sample, and the proxy 
tagSNPs were nominally associated with negative symptoms in females with bipolar 
disorder. This association was stronger in a subsample (n = 36) of women with a 
history of at least one psychotic event (P = 0.002 and P = 0.007).  
 
Paper III: A Study of Ten Genes in the HNK-1 Pathway and Perineuronal Nets: 
B3GAT2 is associated with schizophrenia in two large European Multi-Center Case 
Control Samples 
 
To investigate if the candidate genes are associated with schizophrenia we used a total 
genotyped sample of 849 schizophrenia cases and 1602 controls, but some samples 
were only genotyped for a few tagSNPs using the Taqman assay, and the numbers for 
the best SNP are therefore 823 cases and 1532 controls. The final coverage of common 
HapMap SNPs by the genotyped tagSNPs (r2≥0.8; MAF≥5%), using an updated 
HapMap data release (Data Rel Jan07), was ≥90% for 9 genes, and 80% for B3GAT1. 
The overall FST was 0.0002, and the gene-based FSTs between -0.00003 and 0.0009, 
indicating general allele frequency homogeneity between samples. Five of the 104 
tagSNPs analyzed were nominally associated with schizophrenia in both the allele-
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based test (0.005≤P≤0.05), as well as when testing the SNPs for additive effects in a 
logistic regression model (0.004≤P≤0.05). These SNPs were all located in a region of 
high D’-based LD in the first intron of B3GAT2. The nominally associated SNPs are 
still point-wise significant after calculating the empirical P-values by permuting the 
case control status, but none of the SNPs remain significant after correction for 
multiple testing.   
 
As a follow up we attempted to replicate the findings using already present GWAS 
data in the SGENE-plus sample, comprising of 2,663 cases and 13,498 controls. The 
optimal proxy SNPs were searched for in the B3GAT2 gene, and in an estimated LD 
block spanning the 5’ start site (approximately 17 kb upstream). All five initial 
tagSNPs were represented by proxy SNPs with HapMap-based r2=0.61-0.95. Three of 
the five nominally associated markers were represented by the same proxy SNP, which 
was associated with schizophrenia in the SGENE-plus sample (P=0.044). These four 
SNPs were located in the same estimated LD block (based on HapMap CEU), together 
with a fourth SNP genotyped in our Scandinavian sample, with a proxy SNP also 
nominally associated in SGENE-plus (P=0.014). The major alleles conferred a risk 
effect for the four initial tagSNPs and the two proxy SNPs. None of the other 27 SNPs 
genotyped by us were in higher r2-based LD with the two associated SGENE-plus 
SNPs, than those nominally associated. The combined P-value for the most associated 
SNP and its SGENE-plus proxy was 0.002. 
 
Forty-two SNPs were tested for association with IQ, measures of learning and 
memory, and PANSS positive and negative sum scores in Norwegian patients (n=116; 
n=145 for the PANSS analysis) and the first two endophenotypes also in controls 
(n=273). Forty-four SNPs were tested for association with AAO, in a larger 
Scandinavian case sample (n=801). Each SNP was tested under a recessive, dominant 
and additive disease model. None of the SNPs associated with schizophrenia in both 
the SCOPE and SGENE-plus sample were associated with any of the 
endophenotypes/clinical subtypes in cases, but the risk allele homozygote of one of the 
other two findings in SCOPE was nominally associated with lower scores in the two 
WMS tests in controls (measuring learning and memory), compared with the 
heterozygotes and major allele homozygotes. The same homozygotes have non-
significantly lower scores in the smaller case sample. None of the other tagSNPs were 
significantly associated if corrected for the tests performed. Thirteen SNPs were 
nominally associated with more than one subphenotype, or in both cases and controls 
for the cognitive measures. One B3GAT2 tagSNP was associated with four out of five 
cognitive test scores in controls (IQ, verbal memory, visual memory, verbal learning), 
and with IQ in patients. Another tagSNP was also associated with IQ in both cases and 
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controls, and there was an interaction effect between case control status and genotype 
for both tagSNPs (P=0.003). These markers are in moderate LD (r2=0.53) and located 
in the second intron of B3GAT2, in an estimated LD block 3’ of the one harboring the 
SNPs associated with schizophrenia.  
 
Paper IV: A possible association between schizophrenia and GRIK3 polymorphisms 
in a multicenter sample of Scandinavian origin (SCOPE) 
 
To test potential association between tagSNPs in GRIK3 and schizophrenia, as well as 
with the extent of positive and negative symptoms, we used a sample of 839 
schizophrenia cases + 1,473 controls. Thirty tagSNPs were successfully genotyped and 
their final coverage of common HapMap SNPs (r2≥0.8; MAF≥5%; Data Release 
Jan07) was 72%. Four tagSNPs were nominally associated with schizophrenia in both 
allelic and genotypic tests (P≤0.05), and for three of these the ORs pointed in the same 
direction in the combined and three Scandinavian sample(s) separately. The Nyholt-
corrected significance threshold was P=0.0022, and one of the tagSNPs lead to a P-
value of 0.001 in the combined sample and P=0.00009 in the Swedish sub sample. 
When combining multiple alleles using 2-, 3-, and 4-marker sliding window haplotype 
analysis over the whole gene region, none of the obtained associations were significant 
after permutation-based correction for multiple testing. When combining alleles of the 
four most associated tagSNPs, the strongest finding was a 2-marker haplotype of the 
major alleles (P=1.0210-5, OR(95%CI)=1.50(1.25-1.81)). To investigate if the 
tagSNPs associated with schizophrenia diagnosis also exert effects on the degree of 
positive or negative symptoms, PANSS measures in a Norwegian patient sub sample 
(n=129) were used. There was no association between risk tagSNPs and the PANSS 
positive sum scores. In contrast, there were nominal associations between two of the 
tagSNPs and PANSS negative sum scores, but this was not significant after correcting 
for all tests performed. 
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8. Discussion 
8.1 Findings and interpretations 
The four papers that form the basis of this thesis are all genetic association studies 
aimed at investigating the role of common variants in schizophrenia susceptibility, 
with special focus on neurodevelopment. Genes involved in neuronal migration and 
the formation of perineuronal networks, a glutamate receptor subunit gene, and an 
interactor of DISC1, are included in Paper I-IV. In total, tagSNPs in 30 different 
genes have been tested for association with schizophrenia, in a homogenous 
Scandinavian sample set. 
 
The strongest finding was the association of a 2-marker haplotype of common alleles 
in GRIK3 (Paper IV), and one of the tagSNPs in the associated haplotype was 
associated in the single marker allele-based test after correcting for the 30 tagSNPs 
assessed. Other results are at the nominal association level (P≤0.05), and did not 
remain significant after correction for multiple testing within each of the four papers. 
However, for the association with tagSNPs in B3GAT2 (Paper III), two proxy SNPs 
were also associated in a large multi-national European sample, which strengthens this 
finding. The nominal tagSNP associations in the remaining papers should be viewed as 
findings in need of replication, albeit generated in a homogenous population, with 
potential value in creating new hypotheses (see sections 8.1.2, 8.1.3, 8.1.4) or for 
future meta-analyses. The lowest nominal P-values in Paper I were for tagSNPs in 
neuronal cell adhesion molecule gene MDGA1, and tagSNPs in PDE4B were 
nominally associated with both schizophrenia and bipolar disorder in Paper II. In 
addition, nominal associations were present for DLX1, RELN, ITGA3, SPARCL1, and 
ASTN1 (Paper I). Furthermore, totally negative findings are thereby presented for the 
other 21 genes investigated, although we cannot exclude that there are common 
variants of weak effect in these genes, due to power limitations (see section 8.2.3). 
 
8.1.1 Major risk alleles in B3GAT2 and GRIK3 
The initial nominal association findings for B3GAT2 were replicated in an independent 
sample set. Specifically, three of the five nominally associated tagSNPs were 
represented by the same proxy SNP, which was associated with schizophrenia in the 
large multi-center replication sample. These four SNPs were located in the same 
estimated LD block (based on HapMap CEU), together with a fourth SNP genotyped 
in our Scandinavian sample, with a proxy SNP also nominally associated in the 
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replication sample. The initial best hit and its proxy SNP are only in moderate 
HapMap-based LD (r2=0.64), which could explain why the combined meta-analysis P-
value was just slightly lower than half the initial P-value. The potential functional 
variant might be more efficiently tagged by the initial than the replication SNP, 
resulting in a weaker replication association despite the follow-up sample being much 
larger. 
 
The major alleles conferred a risk effect for the four initial tagSNPs and the two proxy 
SNPs, and are therefore frequent also in the general population, which have been 
reported previously for other loci associated with schizophrenia [Ingason et al., 2007], 
and bipolar disorder [Wellcome Trust Case Control Consortium, 2007]. Since the 
genetic architecture in psychiatric illness is complex, with potential common 
functional alleles exerting a modest effect, healthy subjects having some of the risk 
alleles would then not carry detrimental combinations of additional risk variants 
potentially present in the psychiatric patients.  
 
B3GAT2 encodes one of the two key enzymes regulating the biosynthesis of the 
carbohydrate neural epitope HNK-1, which is involved in processes such as neuronal 
cell adhesion, and synaptic plasticity [Kleene and Schachner, 2004; Morita et al., 
2008]. B3GAT2 was highly expressed in several regions of mouse brain, such as the 
CA2/CA3 hippocampal subfield, neocortical layers V and VI, and several nuclei of the 
thalamus [Inoue et al., 2007]. In mice deficient for the B3GAT1 gene, which is also 
involved in HNK-1 biosynthesis, the widely distributed HNK-1brain expression was 
nearly completely lost [Yamamoto et al., 2002]. However, smaller amounts of HNK-1 
were expressed on neurons in the cerebral cortex and hippocampus, and specifically on 
neocortical neurons in PNs, probably synthesized by B3GAT2. Highly speculative, 
B3GAT2 SNPs associated with schizophrenia in our study might be linked to 
functional variants affecting B3GAT2-dependent HNK-1 biosynthesis in PNs. In turn, 
HNK-1 perturbations might influence its main carrier TNR, which was shown to be 
important for PN composition [Bruckner et al., 2000]. Abnormal PN formation could 
lead to excessive synaptic pruning during brain maturation, which has been suggested 
as a susceptibility factor for schizophrenia [Karlsgodt et al., 2008], in line with the 
reduced cortical thickness and dendritic spine density reported for schizophrenia 
patients [Glantz and Lewis, 2000] 
The haplotype combination of the major alleles of two tagSNPs in GRIK3, were 
significantly associated with schizophrenia (Table 4). If being conservative, 430 tests 
between genetic variation and the schizophrenia phenotype, have been performed in 
Paper IV (30 tagSNPs in the combined sample x 2 tests, 90 x 2 tests in the three 
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countries separately, 84 sliding window haplotype tests, 11 multimarker combinations 
of the four best tagSNPs). However, all these tests are not independent, and tagSNPs 
only associated in one of the country-based sub samples have not been a discovery 
focus. The corrected P-value for the best 2-marker combination, with the 430 tests, is 
0.0044. 
By combining alleles of SNPs in haplotype tests, specific haplotypes might more 
efficiently tag a potential functional variant, compared with the single SNPs alone. The 
two mentioned GRIK3 tagSNPs are in low LD (D’=0.38, r2=0.10), and present in 
distinct LD blocks, which were estimated using the solid spine method and SNP 
genotypes for the HapMap CEU population. The haplotype association implies that 
having both the common T and C alleles of the two tagSNPs is related to an increased 
risk for schizophrenia. The estimated T-C haplotype is present in 89% of the cases and 
85% of the controls. The combined risk allele frequencies in cases, controls, and in 
those HapMap populations where the SNPs are polymorphic, are given in Table 4. The 
test for homogeneity of ORs between the three country strata for tagSNP rs6671364 
was nominally significant, reflecting the fact that the OR for the major allele was 
larger in the Swedish sub sample, compared with the other two, although the same 
alleles conferred “risk” in all three groups.   
  
Table 4. Major allele frequencies and allele- and haplotype-based association results for the two 
tagSNPs in the significantly associated GRIK3 2-marker haplotype 
  Risk Minor     HapMap Rel 271 Rel 241 Allelic Haplotype 
tagSNP allele Allele Cases Controls CEU MEX TSI CEU Assoc T-C assoc 
rs6671364 T C 0,920 0,887 - - - 0,833 0.001  
rs17461259 C T 0,943 0,920 0,920 0,940 0,881   0.006 1.0·10-5 
CEU, Utah residents with Northern and Western European ancestry from the CEPH  
collection; MEX, Mexican ancestry in Los Angeles, California; TSI, Toscans in Italy 
1HapMap release 27 represents Phase II+III, and release 24 is part of Phase II. 
 
GRIK3 is one out of five KA ionotropic receptor subunits, and was one out of two KA 
subunits predominantly expressed in fetal cortex already in the first trimester [Ritter et 
al., 2001], suggesting an important role in neurodevelopment. Also, the three 
ionotropic glutamate receptor subtypes were shown to have distinct subunit binding 
patterns in cortical and subcortical regions during the second trimester [Lee and Choi, 
1992]. GRIK3 mRNA expression was lower in the frontal cortex of postmortem brain 
tissue from neuroleptic-free (longer than 6 months) schizophrenia patients, compared 
with controls and schizophrenia patients receiving antipsychotic medication, and the 
expression level was shown to be negatively correlated with time without treatment 
before death [Sokolov, 1998]. In an additional post mortem study, the GRIK1/2/3 
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immunoreactivity was reduced in hippocampal regions from schizophrenia patients 
compared with controls and bipolar disorder patients [Benes et al., 2001].  
 
As can be seen in the Table 4, GRIK3 allele frequencies in controls are similar or equal 
in the HapMap CEU population, and like the B3GAT2 SNPs, the major alleles are 
conferring the risk effect. The six B3GAT2 SNPs are located in the first intron, and the 
two GRIK3 tagSNPs are located in introns 13 and 2. The potential functionality of 
these SNPs is not known and they have not been associated with schizophrenia 
previously.  
 
 
8.1.2 Schizophrenia and neuronal migration  
Out of 18 genes investigated in Paper I, six nominally associated tagSNPs, including 
the strongest finding, were located in MAM domain containing 
glycosylphosphatidylinositol anchor 1 (MDGA1), which encodes a cell adhesion 
molecule shown to be important for radial glial guided neuronal migration [Takeuchi 
and O'Leary, 2006]. Five out of six MDGA1 tagSNPs were nominally associated in the 
allele-based test, and the same alleles conferred “risk” in the combined and each 
separate Scandinavian sample, which strengthens the uncertain finding. 
 
The genes included in Paper I are encoding proteins either involved in the adhesion 
between radial glial fibers and migrating neurons (four genes, 102 tagSNPs), affecting 
the rearrangements of the cytoskeleton to influence cell polarity or motility during 
migration (eleven genes, 110 tagSNPs), or both of these domains (RELN, 71 tagSNPs), 
as well as two transcription factors affecting neuronal migration (7 tagSNPs). All of 
the five genes (MDGA1, RELN, ITGA3, ASTN1, SPARCL1) involved in neuron-glial 
adhesion have at least one nominally associated tagSNP in the present association 
study. Potentially could the process of cell adhesion during neuronal migration be of 
interest for further studies within schizophrenia genetics. However, the best finding for 
MDGA1 was above the Nyholt-corrected significance threshold, and no association 
tests with 2- to 4-marker haplotypes achieved higher significance levels, making such 
an implication highly speculative. 
 
In addition to the five mentioned genes, two out of only three genotyped tagSNPs in 
transcription factor DLX1 were nominally associated with schizophrenia, a gene 
important for the tangential migration of GABAergic interneurons [Anderson et al., 
1997]. Interestingly, the number of DLX-1 expressing neurons was previously shown 
to be reduced in the mediodorsal nucleus of the thalamus of psychosis patients 
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[Kromkamp et al., 2003], and reduced total neuron count has been reported in the 
same brain region of schizophrenia patients [Popken et al., 2000]. 
 
8.1.3 Common genetics for schizophrenia and bipolar disorder 
In Paper II, tagSNPs in PDE4B were genotyped in both a schizophrenia and bipolar 
disorder case-control sample, to investigate if PDE4B might be part of the suggested 
genetic overlap between the two disorders [Lichtenstein et al., 2009]. PDE4B interacts 
with DISC1, which is an indicated risk factor for severe psychiatric illness both 
involving schizophrenia, schizoaffective, and bipolar disorder [Porteous et al., 2006]. 
The segregation of a balanced translocation directly disrupting PDE4B, with psychotic 
disorder in a Scottish family, implicated PDE4B as a schizophrenia risk factor [Millar 
et al., 2005]. PDE4B is a phosphodiesterase that hydrolyze the second messenger 
cAMP [Houslay and Adams, 2003], and its interaction with DISC1 was shown to be 
regulated by cAMP levels, with PDE4B release from DISC1 in response to cAMP 
elevation [Millar et al., 2005]. PDE4 genes are orthologous to the dunce gene in 
Drosophila melanogaster, and dunce mutants show impaired learning and memory 
[Davis et al., 1995]. The selective PDE4-inhibitor Rolipram has antidepressant effects 
in humans [Zhu et al., 2001], as well as antipsychotic-like behavioural effects in mice 
[Kanes et al., 2007] and rats [Siuciak et al., 2007].  
  
There were tagSNPs nominally associated with both schizophrenia and bipolar 
disorder in our combined sample and gender-stratified subsamples. The subdivision 
based on gender was performed based on a previous study reporting an association 
between PDE4B and schizophrenia, restricted to females [Pickard et al., 2007]. One 
drawback with the study is the fact that most tagSNPs genotyped in the two samples 
are non-overlapping, since they were selected and genotyped at different time points. 
As a first screen of the large gene region, tagSNPs in the schizophrenia sample was 
chosen with a MAF cut-off of 20%, and in the bipolar disorder sample this was 
increased to include also tagSNPs with a MAF ≥ 5%. However, all the nominally 
associated tagSNPs in the schizophrenia sample have either been genotyped 
themselves or by proxies in the bipolar disorder sample.  
 
Two of the tagSNPs nominally associated in schizophrenia females had proxies which 
were nominally associated in the total bipolar disorder sample. Based on LD block 
estimation using the HapMap CEU population and the solid spine method (D’>0.8; 
adjacent blocks with multiallelic D’ values>0.95 were joined), the four SNPs were 
located in the same block, surrounding the splice site for the PDE4B isoform 3. In a 
recent screen for regulatory regions in schizophrenia candidate genes, including 
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PDE4B, with a chromatin immunoprecipitation-based method, brain tissue from two 
second-trimester fetuses was used to capture epigenetic events during brain 
development [Pedrosa et al., 2009]. In the analysis, the isoform 1 and 3 promoters 
were detected, with the latter being located in between the two markers in each of the 
nominally associated schizophrenia tagSNP-bipolar proxy SNP pairs, suggesting that 
these SNPs might tag functional variants affecting promoter function. Decreased 
PDE4B3 expression in cerebellar post mortem brain tissue from patients with bipolar 
disorder compared with controls has previously been reported [Fatemi et al., 2008]. 
Based on the opposing directions of association in our study, with major and minor 
allele homozygotes conferring a risk effect for schizophrenia and bipolar disorder, 
respectively, functional variants in the PDE4B3 might exert a balancing role. Although 
highly speculative, depending on the genetic make-up on other susceptibility loci, one 
functional genetic effect could predispose to the psychiatric phenotype of 
schizophrenia, and the opposing effect to bipolar disorder.  
 
In a markedly smaller subset of Norwegian patients, the same two schizophrenia 
tagSNPs were associated with positive symptom scores, and the two bipolar disorder 
proxy SNPs nominally associated with negative symptom scores if investigated in 
females only. The latter association was more prominent in females with a history of at 
least one psychotic event, but this group only consisted of 36 women.  
 
One of the three highlighted putative regulatory regions reported in the study by 
Pedrosa et al. described above, is encompassed by a two-marker haplotype associated 
with schizophrenia in another case-control study [Fatemi et al., 2008]. One of these 
two markers is genotyped in both our schizophrenia and bipolar disorder, but is only 
nominally associated with bipolar disorder.  
 
 
8.1.4 Gender-specific associations of PDE4B tagSNPs with 
schizophrenia 
Before we statistically analyzed the PDE4B tagSNP genotypes in the SCOPE sample, 
a gender-specific association of an individual three-marker haplotype within intron 3 
of PDE4B was published [Pickard et al., 2007]. The specific haplotype conferred a 
protective effect against schizophrenia in a Scottish case-control sample, but only in 
females. Therefore, we tested the PDE4B tagSNPs for association both in our total 
sample, and in women and men, separately. In line with the previous report, four 
tagSNPs were exclusively nominally associated in women, compared with none in 
only men, in addition to two nominally significant tagSNPs in the total sample.  
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Associations only in female subjects, between gene variants and both schizophrenia 
and bipolar disorder, have previously been reported for other loci [Hennah et al., 2003; 
Thomson et al., 2005a; Thomson et al., 2005b]. A haplotype in the DISC1 gene was 
significantly associated with schizophrenia [Hennah et al., 2003], and another DISC1 
haplotype was associated with bipolar disorder [Thomson et al., 2005a], both only in 
women. Based on five populations, there was a female-specific association between an 
intronic SNP in RELN and schizophrenia, with a significant gene-sex interaction 
[Shifman et al., 2008]. We did not test for such a formal interaction, and the gender-
specific effect of PDE4B based on associations in females only, should be interpreted 
with caution [Patsopoulos et al., 2007]. 
 
On the schizophrenia phenotype level, there seems to be differences between males 
and females, which might reflect underlying genetic differences [Leung and Chue, 
2000]. Although still controversial due to methodological problems, the schizophrenia 
incidence was shown to be increased in men in a recent comprehensive meta-analysis, 
with a risk ratio of 1.35 relative to women, when controlling for the possible bias from 
the factors age, diagnosis criterion, and inpatient/outpatient sample inclusion [Aleman 
et al., 2003]. 
 
8.1.5 Associated genes and regional schizophrenia linkage 
In this section, the genetic regions highlighted in the thesis are placed on the 
chromosomal map of schizophrenia linkage. Linkage data on the same or surrounding 
genetic sections, as those harboring the main nominal/significant findings in Paper I-
III, are put forward, specifically this includes: B3GAT2 (6q13; Paper III), PDE4B 
(1p31.3; Paper II), and MDGA1 (6p21.2; Paper I). 
The first suggestive evidence for the involvement of the 6q genome region in 
schizophrenia, was based on a genome scan of chromosome 6 showing an excess of 
identity by descent allele sharing for microsatellite markers on 6q13-q26, in both an 
initial and a replication multiplex family sample set [Cao et al., 1997]. The most 
centromeric marker on 6q was located in 6q13, about 52 kb upstream (towards the 
centromere) of the B3GAT2 gene. When excluding families without genotypes for both 
parents, all maximum likelihood scores (MLSs) in 6q (6q13-6q27) were greater than 
0.97, and in the replication sample the region with MLSs ≥ 1 started in the 6q13-q16.1 
interval and reached 6q22.31. However, the actual MLS peaks were at 6q21-22 and 
6q16, in the initial and replication set, respectively, which might reflect a difficulty in 
locating the causative locus [Roberts et al., 1999]. Combining the latter sample with an 
additional replication set gave rise to significant linkage to 6q16 (MLS=3.82; 
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P=1.410-5) [Martinez et al., 1999], which was later supported [Levinson et al., 2000]. 
Genome-wide significant linkage for 6q21 and bipolar disorder was reported in a large 
combined analysis of 1,067 families [McQueen et al., 2005]. A balanced 6;11 
chromosomal translocation with the breakpoint at 6q14.2 was partially co-segregating 
with schizophrenia spectrum disorder in a family [Holland and Gosden, 1990],  and 
another translocation t(5;6) (p13;q15) was present in a patient with acute paranoid 
psychosis [Axelsson and Wahlstrom, 1984], both implicating regions centromeric of 
the 6q16 linkage peak, in schizophrenia susceptibility. Genome-wide suggestive 
linkage was also reported for 6q12 and suicide attempts in major depression [Zubenko 
et al., 2004].  
 
In a recent meta-analysis of 32 whole-genome linkage scans of schizophrenia, one of 
the ten genome bins which met the empirical “aggregate” criteria for genome-wide 
significant linkage, was 1p32.2-p31.1, containing PDE4B (1p31.3) [Ng et al., 2008], 
but the nearby region including GRIK3 (1p34-33) has to our knowledge not been 
linked with schizophrenia. 
 
Initial linkage reports of 6p, implicated a susceptibility locus for schizophrenia on 
6p24-22 [Schwab et al., 1995; Straub et al., 1995; Wang et al., 1995], harboring the 
DTNBP1 candidate gene on 6p22.3 [Straub et al., 2002]. The marker closest to 
MDGA1 (6p21.2), which was genotyped in the more comprehensive study by Straub et 
al. (including the pedigrees used by Wang et al.) as well as an additional investigation 
[Schwab et al., 1995], was non-significant and positioned 1.2 Mb away on 6p21.31. 
However, in a subsequent study, potential linkage was suggested based on the same 
marker, in a two-stage genome-wide screen [Moises et al., 1995]. In a large meta-
analysis of genome-wide linkage scans, the linkage region 6p22.3-p21.1 was proposed 
[Lewis et al., 2003], encompassing MDGA1. Also, significant and suggestive linkage 
between the eye tracking dysfunction schizophrenia endophenotype, and 6p21.1, was 
shown [Arolt et al., 1999], supported by others [Matthysse et al., 2004].  
 
8.1.6 Genetic effects on symptoms, neurocognition, and age at      
onset 
The diagnosis of schizophrenia embraces a heterogeneous group of patients, with 
varying degree of positive and negative symptom severity, and cognitive performance. 
To genetically assess a potentially more homogenous phenotype, endophenotypes and 
clinical characteristics have been used in three of the thesis papers. It has been 
suggested that besides genes conferring disease susceptibility, additional gene variants 
may only exert their function on the clinical expression of the phenotype, so called 
 61 
 
modifier genes, and others might be both susceptibility and modifier variants [Fanous 
and Kendler, 2005]. In the present work we investigated if the genes could be both 
susceptibility and modifier variants. 
 
In Paper II-IV, we searched for gene variants with a potential effect on the extent of 
positive and negative symptoms in schizophrenia patients, as measured by the PANSS. 
Paper II includes both schizophrenia and bipolar disorder patients, and those results 
were therefore integrated in a combined discussion of data on both disorders in section 
8.1.3. The negative, but not positive, symptom dimension was previously shown to be 
associated with cognitive dysfunction, as measured with a number of different tests of 
learning and memory [O'Leary et al., 2000]. Therefore, genetic variants involved in 
cognitive deficits might also be associated with more severe negative symptom scores. 
However, there were no significant associations between tagSNPs and symptom scores 
for GRIK3 (Paper IV) or B3GAT2 (Paper III).  
 
In Paper III, we also investigated age at onset and neurocognitive measures of 
learning and memory, the latter in both cases and controls. Two tagSNPs, in distinct 
LD blocks and separate introns of B3GAT1, were nominally associated with symptom 
sum scores as well as one of the cognitive measures in the patients. Major allele 
homozygotes had lower IQ and higher positive symptom sum scores for one tagSNP, 
and heterozygotes had higher measures of verbal learning (CVLT) and lower negative 
sum scores, as compared with both homozygotes, for the other tagSNP. The verbal 
learning measure was similar to the test most significantly correlated with the negative 
symptom dimension [O'Leary et al., 2000]. Two B3GAT2 tagSNPs was nominally 
associated with IQ scores in both cases and controls, with one of them also associated 
with three additional cognitive test scores in controls, suggesting an effect of B3GAT2 
on cognitive function in both groups. There was an interaction effect between case 
control status and genotype for both tagSNPs, reflecting gradually higher IQ scores in 
controls in contrast to lower IQ scores in cases, with the number of minor alleles (for 
the tagSNP with sufficient numbers in each genotype group). 
 
There are several limitations of our analyses of quantitative measures and gene 
variants. Regarding the use of the PANSS scores as clinical subtypes of schizophrenia 
and bipolar disorder patients, there is an uncertainty to what extent these scores are a 
true reflection of the clinical picture caused by intrinsic factors. The scores vary 
substantially over time and with treatment, especially the positive but also negative 
symptoms [Lindenmayer et al., 2007]. Other studies have shown genetic association to 
symptom scores in schizophrenia, for genes such as DAO and DTNBP1 [Corvin et al., 
2007; Corvin et al., 2008; Fanous et al., 2005]. However, the symptom measures have 
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differed slightly between studies: one group [Corvin et al., 2007] used PANSS-derived 
symptom factors assessed on the basis of the worst documented episode of illness, 
compared to the reflection of the last week in our studies, and another group [Fanous 
et al., 2005] used life-time ratings of clinical features according to the Operational 
Criteria checklist for psychotic illness. Therefore, a comparable measure reflecting a 
longer time-frame would have been optimal also in our study, although the included 
individuals are mainly from out-patient clinics, where patients are treated in stable 
phases. It is possible that persisting high PANSS levels in this population can reflect 
treatment resistant subjects, and specific sub-groups of patients. However, only a 
restricted number of patients have symptom scale scores and neurocognitive measures, 
which imply that the nominal association findings found by us are preliminary and 
might represent type I error. 
 
8.2 General methodological issues 
8.2.1 The schizophrenia and bipolar disorder phenotype  
The diagnosis of schizophrenia and bipolar disorder are both based on descriptive 
criteria on the basis of clinical symptoms, without objective biological measures for 
validation, since the pathogenic mechanisms are largely unknown. However, both 
clinically diagnosed schizophrenia and bipolar disorder has a high estimated 
heritability, providing evidence for an important biological basis. If this biological 
etiology is largely shared within the separate schizophrenia and bipolar disorder 
patient groups, if there is a common background spanning these two groups and also 
major depression and autism at the far ends, and/or if there are several 
“schizophrenias” and “bipolar disorders” caused by numerous distinct biological 
mechanisms, remains to be answered. There is new research in favour of the presence 
of a psychiatric continuum including both shared and unique biology. Increased 
knowledge will guide both future diagnostic tools and development of new 
medications. Today’s psychiatric diagnoses are based on two main diagnostic systems, 
the DSM-IV and ICD-10, with both being represented in this thesis.  
It has been shown that there is high concordance between the ICD and DSM systems 
(pairwise concordance rate (CR)>0.70, >0.70) [Jakobsen et al., 2006]. The vast 
majority of the patients (96%) who fulfilled the ICD-10 criteria of schizophrenia also 
complied with the corresponding DSM-IV standards. The main difference between the 
schizophrenia diagnoses in the two systems is the time factor, where symptoms should 
have been present for 6 months in DSM-IV/III-R and one month in ICD-10. The 
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diagnosis of schizophreniform disorder which is given to patients with symptoms of 
schizophrenia that do not reach the 6 month-criteria in DSM-IV/III-R, is to a high 
extent included in the schizophrenia F20 diagnosis in ICD-10. Potential differences in 
the patient phenotype in our studies, due to differences between the three Scandinavian 
countries, was corrected for by including the covariate “sample origin” in all main 
analyses.  
 
In the initial genetic association tests in Paper I-IV, a defined broad diagnosis of 
schizophrenia has been implemented, including patients with schizophrenia, 
schizoaffective disorder, and schizophreniform disorder. In the case of association 
tests with bipolar disorder, bipolar disorder type I, II, and NOS have been included. 
Depending on if the biological target mechanisms evaluated in a hypothesis-driven 
candidate gene study, are in fact involved in a pathway with importance only for a 
subset of patients with strict schizophrenia diagnosis, or in a pathway affecting the 
propensity to develop psychosis, the choice of either strict schizophrenia or a broader 
schizophrenia spectrum disorder phenotype would affect the results. Since there are 
several studies showing strengthened findings with a broad phenotype, both including 
schizophrenia, schizoaffective, and schizophreniform disorder, as well as bipolar 
affective disorder [O'Donovan et al., 2009], we focused on a broad schizophrenia 
group to maximize the sample size.      
 
In Paper I, we re-analyzed all tagSNPs nominally associated with broad 
schizophrenia, using a narrow schizophrenia group, only including patients with the 
strict schizophrenia diagnosis. Despite the decrease in sample size (Nbroad=839; 
Nnarrow=736), the results were similar. 
 
8.2.2 Strategies for picking tagSNPs 
The international HapMap project was launched with a goal to identify SNPs, and to 
investigate the pattern of LD, throughout the human genome. The knowledge of the 
LD pattern between gene variants can subsequently be used for gene-wide assessment 
of candidates in association studies. To reduce marker redundancy, a set of tagSNPs 
can be genotyped, which capture information on other non-genotyped common 
variants in high LD. The tagSNPs can be selected based on public projects such as 
HapMap or a subset of individuals from the study in question. Hopefully the tagSNPs 
capture both known variants, as well as potential unknown functional loci in the 
candidate region. There are three commonly used methods for picking tagSNPs, 
namely pairwise, multimarker, and haplotype-based tagSNP selection [Goode et al., 
2007]. In more detail, the first is based on correlating each known SNP with a SNP to 
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be genotyped, the second on correlating known SNPs with a single SNP or a 
combination of SNPs to be genotyped, and the third is based on representing each 
estimated haplotype of interest with a set of SNPs to genotype. If the functional variant 
is actually one of the genotyped tagSNPs, or a SNP in strong LD with one of the 
tagSNPs, using pairwise and multimarker methods would be the optimal strategy. On 
the other hand, if the haplotype tagging SNPs define a haplotype which carry the 
functional allele, haplotype-based methods would be optimal. At the design phase of 
an investigation, it is therefore difficult to know which method would be the best one 
in that particular association study. In Paper I-IV, pairwise tagging based on HapMap 
data was implemented, which was the method presented in a recent publication on 
marker selection in Nature protocols [Pettersson et al., 2009]. Each tagSNP represents 
either only itself, if not in LD with any other known HapMap SNP, or a tagged bin, 
which includes a set of covered markers ranging from one and up to several tens.  
 
8.2.3 Power, control selection, and population stratification 
The power of a genetic association study is obviously based on the size of the sample, 
but is also highly influenced by several additional known as well as unknown factors 
[McGinnis et al., 2002]. In the publicly available Genetic Power Calculator 
(pngu.mgh.harvard.edu/~purcell/gpc/cc2.html), the power calculations are based on 
the following features: disease-causing allele frequency, heterozygote OR, risk 
homozygote OR, D’ between marker and disease allele, marker allele frequency, 
number of cases and controls, disease prevalence, and whether the controls are 
unselected or not. The sample size was shown to be minimized when the marker and 
disease allele frequencies are equal and 0.5, when the mode of inheritance is dominant 
or recessive (either one or the other depending on OR and disease allele frequency), 
and if the linkage disequilibrium between disease and marker polymorphism is 
complete [McGinnis et al., 2002]. The power of the sample used in Paper I (including 
the highest number of genes out of the four thesis papers) for a set of different 
conditions is given in Figure 4. The power is calculated for a range of ORs for four 
different MAFs, at the nominal significance level of P=0.05. The mean MAF in Paper 
I was 26%. As can be seen the power for SNPs with allele frequencies in the lower 
frequency range is not sufficiently high, which can result in type II errors. The Power 
when ORhomozygote=1.5 (additive inheritance model) was 39, 63, 88, and 91 % for 
MAFs 5, 10, 25, and 50%, respectively. For the Nyholt-corrected threshold given in 
Paper I (P=0.00027), the power is substantially lower, being 37% for ORhomozygote=1.5 
and MAF=25%, as an example. 
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Figure 4. Power calculations based on the 839 cases and 1473 controls in Paper I using Genetic 
Power Calculator. The following settings are fixed: r2=1, P=0.05, and additive inheritance model. The 
power is given for the allelic association test. 
 
Association studies can be based on genotyping data of either families or unrelated 
individuals. The studies in Paper I-IV are all based on the latter, with a case-control 
design. When using the same number of cases and controls in such a study, roughly 
the same number of affected child and parent trios is required for equal power in the 
family-based design, which means that the family-based sample will need to be 50% 
larger than the case-control sample [McGinnis et al., 2002]. Case-control studies are 
therefore more cost effective. In addition, to boost the power without including more 
cases, the number of unrelated controls can be increased, an approach used in Paper I-
IV, mostly accounted for by the additional Danish controls. The control:case ratio in 
Paper I is 1.76.  
 
In contrast to the parents serving as controls when using trios and the transmission-
disequilibrium test (TDT), the optimal selection of controls for case-control studies is 
more complex. In contrast to family-based association studies, the main concern using 
unrelated cases and controls is the risk for so called population stratification, meaning 
that the two comparison groups have allele frequency differences unrelated to the 
studied phenotype, instead caused by diversity in background population [Cardon and 
 66 
 
Palmer, 2003]. Therefore, population stratification can cause spurious association 
findings. The general criteria for suitable controls are that these should be derived 
from the same population as the cases, in order to serve as representatives of genetic 
make ups not related to the disease under study. For population stratification to be 
problematic in genetic association studies, both differences in disease prevalence and 
allele frequency must be present between cases and controls [Wacholder et al., 2000]. 
Of course, if the presence of different ethnicities between cases and controls is due to 
selection bias, only a difference in allele frequency between ethnicities could cause 
false positive findings. Due to limited evidence showing the actual effects of 
population stratification on type I errors and non-replications, the fear for stratification 
has been viewed as exaggerated [Cardon and Palmer, 2003]. The risk for population 
stratification might mostly be a problem in populations with recent admixture, such as 
African Americans, and for disorders with distinct prevalence across the ancestral 
populations [Freedman et al., 2004]. A minority of individuals in SCOPE has one 
Caucasian parent born in North-Western Europe, but outside Scandinavia, but when 
excluding those patients with one non-Danish parent from the Danish sample this had 
no effect on the association results in that study [Hansen et al., 2007].  
 
The Scandinavian sample used in Paper I-IV, is well suited for genetic studies. 
Scandinavians are genetically homogenous with only recent non-Caucasian 
immigration. In a study of 23 European populations, using SNP-based PCA (≈300,000 
SNPs), it was shown that northern Europeans have higher mean LD and smaller mean 
heterozygosity, compared with southern Europeans [Lao et al., 2008], which is more 
suitable for LD-based association studies. Fifty Danish controls included in the study 
by Lao et al., located in PCA clusters with Norwegians and northern Germans, were 
randomly drawn from the same sample pool as the Danish controls included in SCOPE 
(the SCOPE controls are discussed further below). As a measure on how genetically 
similar the Danish, Norwegian, and Swedish SCOPE controls were, we estimated the 
Fixation index, based on 289 marker genotypes (Paper I), which showed no indication 
of genetic heterogeneity (FST=0.00071). Based on GWAS data, the Norwegian sample 
was shown to be genetically homogenous (Figure 2 & 3), and risk for population 
stratification due to substructures in Norwegian cases and controls does not seem to be 
a concern.  
 
Whether optimal controls should be completely unselected of other phenotypes, or 
being represented by health-seeking individuals with other unrelated disorders, is 
under debate [Zondervan and Cardon, 2007]. In addition, the extent to which the 
controls should be screened for psychiatric illness in schizophrenia studies is not 
straightforward. If the genetic variants under study are involved in the etiology of a 
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broad phenotype including a range of psychiatric disorders, such as depression, 
schizophrenia, autism, and bipolar disorder, the power to detect disease variants would 
decrease if any of the phenotypes were present in controls. On the other hand, 
screening for sub-diagnostic depressive states, would exclude a high number of 
individuals and create a non-representative sample of the general population. In the 
SCOPE sample, the Norwegian and Swedish controls are screened for schizophrenia, 
whereas the Danish controls were randomly selected out of a population of 15,000 
blood donors. Norwegian subjects were additionally excluded if they or any of their 
close relatives had a lifetime history of a severe psychiatric disorder (schizophrenia, 
bipolar disorder and major depression).  
 
8.2.4 Correction for multiple testing 
In the quest for gene variants involved in complex disorders, such as schizophrenia 
and bipolar disorder, a high number of candidate genes have been implied and tested 
for association (www.schizophreniaforum.org/res/sczgene), combined with a current 
wave of whole-genome studies. With the investigation of several genes, different 
markers and marker combinations within each gene, and up to over a million markers 
when assessing the whole genome, comes the risk of false discoveries due to multiple 
statistical comparisons [Sullivan, 2007]. A stringent approach is to use the so called 
Bonferroni corrected significance level, /m, where the original threshold is  and the 
number of independent tests is m. However, most often all tests within an association 
study is not independent, and by the use of an overly conservative threshold true 
effects might be missed. A method where the LD structure between assessed SNPs is 
taken into account when estimating an “effective” number of independent tests was 
suggested [Nyholt, 2004], but also such a threshold might be too conservative 
[Nicodemus et al., 2005]. A proposed better estimate [Cannon et al., 2005] for the 
Nyholt threshold was used in Paper I and IV, where the best nominal P-values were 
above and below the Nyholt significance threshold, in the first and the latter paper, 
respectively. The golden standard for correction of multiple testing is otherwise 
permutation-based, where the case-control status is shuffled, although this is more 
time-consuming and computationally demanding. Permutation-based correction was 
used for single and multi-marker analyses in Paper II and III, with 10-100,000 
permutations.  
 
Independent of which correction-method is chosen, the common procedure for 
candidate gene association studies is to base the correction on the tests performed 
within the actual study, which means that the multiple testing for the whole research 
community is not assessed [van den Oord and Sullivan, 2003]. Also, as in the present 
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thesis (Paper II-IV), endophenotypes and clinical subtypes, in addition to the main 
disease phenotype, are commonly investigated, further increasing the risk of type I 
errors. However, if the probability of excluding false discoveries is maximized, the 
power to detect true effects if present is lowered. In Paper III, we used a non-stringent 
level of nominal association as a first step, and investigated markers with P-values 
below 0.05 in a second replication step in a markedly larger sample. The importance of 
the definition of a “true” replication was highlighted [Sullivan, 2007], and as 
proposed, the replication of tagSNPs in Paper III are based on the “same” SNPs 
(proxy SNPs), the same statistical test (allelic CMH), the same phenotype 
(schizophrenia), and the same direction of association (OR>1 for the same alleles). 
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9. Concluding remarks and future studies 
During the research work in this thesis, which started in the beginning of 2006, the 
field of genetics has evolved rapidly. Only a few years ago, the GWASs which are 
presently delivering huge amounts of exciting data, were at the planning and design 
phase, while the high-throughput genotyping tools emerged and improved.  
 
When designing the PhD thesis, and starting out with the first data analysis, there was 
a lot of focus on specific candidate gene variants as markers of interest, with 
hypothesized functions. We wanted to focus our hypotheses on the genes to be studied, 
and take advantage of the data from the HapMap project in order to search for disease 
association on a gene-wide level, trying to capture most of the common SNPs in the 
regions of interest. The question of whether the HapMap CEU sample, chosen to 
represent Europeans, was comparable to the individuals in today’s Northern Europe, 
was recently answered by Lao et al. [Lao et al., 2008], who used genome-wide 
genotyping data, to demonstrate that the CEU sample individuals are genetically 
North-Europeans.  
The SNPs included in the HapMap database has constantly increased, so the selected 
tagSNPs in 2006 do not cover as much of the variation as those picked later on. In the 
present thesis work, tagSNPs in 30 candidate genes involved in neurodevelopment and 
plasticity, have been chosen and investigated for association with schizophrenia, as 
well as bipolar disorder for one gene, in Scandinavian multi-center case-control 
samples. The importance of large collaborative efforts within the field of genetics has 
the last few years been put in the spotlight, and several multi-national consortia have 
emerged. By taking advantage of already present GWAS data for another markedly 
larger European sample, the association with common variation in the B3GAT2 gene 
in one of the thesis projects, was replicated.     
 
In parallel with the increased amount of SNPs deposited in public databases, the 
interest and importance of CNVs has been raised. For the field of schizophrenia 
genetics, GWAS data on both SNPs and CNVs has provided evidence for both 
common alleles of weak effects and rare alleles with fairly large effects, in disease 
etiology [Owen et al., 2009]. A main challenge for future psychiatric genetics is to 
elucidate the underlying functional effects, both for common SNPs and for the genes 
located in the large deleted regions strongly associated with schizophrenia 
[International Schizophrenia Consortium, 2008; Stefansson et al., 2008]. So far, most 
associated alleles in GWASs are located in non-exonic regions, as well as the tagSNPs 
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associated in this thesis, and different effects on gene expression might be a main 
action for common variants in complex disease [Hardy and Singleton, 2009].  
 
About a year ago, the first individual genome sequenced by the next-generation 
technologies, was published [Wheeler et al., 2008], leading the way for future high-
throughput personal genome sequencing, at lower costs. In the quest for functional 
variants in regions of interest, more efficient sequencing efforts are now possible, of 
importance for trying to find both possible common and rare variants. In the future, 
when hopefully being able to investigate the functional variation associated with 
schizophrenia directly, there will be a time for improved evaluations of the actual 
contribution of common and rare variation to disease susceptibility. 
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10. Conclusions 
 
The main conclusions of this work are: 
 
 
1) Gene variants related to neuronal migration are nominally associated with 
schizophrenia, and therefore of interest for further studies. 
 
2) Variation in the region surrounding the PDE4B isoform 3 splice site, might be 
involved in both schizophrenia and bipolar disorder etiology, and possibly are 
there variants affecting schizophrenia susceptibility only in women. 
 
3) Gene variants in the HNK-1 pathway seem to be associated with schizophrenia, 
based on the replication of initial nominal findings in a large additional 
European sample, for SNPs in B3GAT2. 
 
4) GRIK3 variants were significantly associated with schizophrenia, supporting the 
involvement of glutamate signaling in schizophrenia etiology. 
 
 
The present study provides a basis to gain more knowledge about the molecular 
genetic mechanisms of schizophrenia, and the results suggest that gene variants related 
to neurodevelopment are associated with schizophrenia, thus supporting the 
neurodevelopmental hypothesis.  
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11. Errata 
Paper I: 
Page 1092, Section “Single-Marker Association Analysis”, first sentence: 
“Nineteen markers (out of 289, 6.6%)” should be “Twenty-one markers (out of 289, 7.3%)” 
 
Paper II: 
Page 2, Section “The bipolar case-control sample”, sentence twelve, should read: 
“The first patient group had been diagnosed with SCAN [Wing et al., 1998] interviews 
fulfilling a best estimate diagnosis of bipolar affective disorder according to the ICD-10-
DCR [WHO, 1993] and BPI according to the DSM-IV. 
 
The figure text for the supplementary figure in the supporting information published online is 
missing, and should be:  
 
Supplementary Figure 1. Overview of the SNPs genotyped in the present (Kähler BP and 
Kähler SZ) and the three previously published PDE4B association studies, as well as the 
PDE4B gene structure. The following features are represented (from top to bottom): LD 
blocks estimated based on the BP case control sample; vertical bars representing each SNP 
genotyped (dark grey=not associated, green=associated in the total case control sample, 
red=associated in women, blue=associated in men, bars marked with ‘*’ (from top left to 
bottom right)= rs11208776, rs2186122, rs1937450, rs3009872 (two BP-SZ SNP pairs which 
serve as r2-based proxies for each other), rs1040716, rs910694 (the same associated SNPs in 
two studies)); the exon structure of the three main isoforms given by NCBI (23 december 
2008) (alt 1=a unique alternative exon 1); the basepair position at chromosome 1; a heatmap 
based on the BP case-control sample showing D’ (color coded) and r2 (figures) between SNPs 
(created in Haploview 4.1). 
 
Paper IV: 
Page 244, Section 2.5.3, should read: 
…Cochran-Mantel-Haenzcel test for 2x2xk stratified tables in PLINK (v0.99q-2007) (Purcell, 
2007; Purcell et al., 2007), on the combined sample with population as stratification 
factor. To evaluate the heterogeneity of population- as well as gender- based odds ratios 
(ORs), the Breslow-Day test was performed… 
 
Page 245, Section 3.2, 2nd paragraph, should read: 
There were no significant OR heterogeneity between the three nationalities or between 
genders, except for marker rs6671364 with nominally significant heterogeneity between 
nationality strata (P=0.027; Breslow-Day test).  
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The following changes of the submitted thesis have been made in the printed version:  
 
 The reference “Sobeih & Corfas, 2002” referred to on page 19, line 10, was added to 
the reference list: 
 
Sobeih MM, Corfas G. 2002. Extracellular factors that regulate neuronal migration in the central 
nervous system. Int. J. Devl Neuroscience 20:349–357. 
 
 On page 29, line 9, the first reference given was “2008”, but changed to: 
“International Schizophrenia Consortium, 2008” 
 
 In the figure text for Figure 2, page 38, the two different pictures were referred to as 
“to the left” and “to the right”, which was changed to: “on top” and “below” 
 
 In Table 2, page 42, the header and bottom row of the table was changed: 
Now:           Allele   A a  Total 
Previously:  Allele  A A  Total 
 
Now:           Total  A a N 
Previously:  Total A A N 
 
 In Table 3, page 42, the header and bottom row of the table was changed: 
Now:           Genotype AA Aa aa Total 
Previously:  Genotype AA Aa Aa Total 
 
Now:           Total AA Aa aa N 
Previously:  Total AA Aa Aa N 
 
 The reference “(Patil 2001)” referred to on page 44, line 33, was changed to “[Patil et 
al., 2001]”, and added to the reference list: 
 
Patil N, Berno AJ, Hinds DA, Barrett WA, Doshi JM, Hacker CR, Kautzer CR, Lee DH, Marjoribanks 
C, McDonough DP, Nguyen BT, Norris MC, Sheehan JB, Shen N, Stern D, Stokowski RP, Thomas DJ, 
Trulson MO, Vyas KR, Frazer KA, Fodor SP, Cox DR. 2001. Blocks of limited haplotype diversity 
revealed by high-resolution scanning of human chromosome 21. Science 294:1719-23. 
 
 Page 56, first line in section 8.1.2: 
“…in Paper I, the six nominally…”  “…in Paper I, six nominally…” 
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